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ABSTRACT 
Telomeres are protective DNA-protein structures located at the ends of chromosomes. 
Telomeric DNA is maintained by a reverse transcriptase called telomerase that consists of an 
RNA moiety, a catalytic protein subunit (TERT) and auxiliary proteins. In adult human, 85% 
of tumor-derived cells have detectable telomerase activity, whereas in most of somatic cells 
telomerase activity is not detected. Consequently, somatic cells exhibit progressive telomere 
shortening and proliferative failure. Evidence that telomere shortening limits proliferative 
potential was demonstrated by ectopic expression of hTERT. Cells that stably expressed 
hTERT exhibited telomerase activity and indefinite proliferation. There is a striking 
correlation between telomerase activity and hTERT RNA levels in the cells examined so far, 
therefore indicating that regulation of hTERT expression is the limiting step for inducing 
telomerase activity. 
To understand the differential expression of hTERT mRNA between tumor and somatic 
cells, we determined by quantitative RT-PCR the level of hTERT mRNA in telomerase 
positive and negative cells. Telomerase-positive cell lines contained between 0.2 and 6 
molecules of spliced hTERT RNA/cell, whereas no transcripts could be detected in 
telomerase negative cells (<0.004 molecules/cell). Furthermore, intron-containing, immature 
hTERT RNA was detected only in nuclei of telomerase positive cells. These data are 
consistent with a regulation of hTERT RNA at the transcription level.  
To analyze hTERT 5’flanking region, we developed a new GFP-reporter system that is 
not limited by a low efficiency of transfection. The hTERT-GFP reporter constructs consist of 
fragments of the hTERT 5’flanking region fused to GFP. We found that the hTERT-GFP 
reporters were not expressed in telomerase negative primary cells but in telomerase positive 
cells but also in the telomerase negative cell line, 21NT-chromosome 3. Thus, in the latter 
cells, in which transfer of chromosome 3 extinguished hTERT RNA, the hTERT-GFP 
reporters containing 5’flanking region up to 7.4 kb upstream of the translation start site did 
not faithfully mimic endogenous hTERT. 
We investigated the possible function of c-Myc, a known regulator of hTERT, upon 
transfer of chromosome 3 in 21NT-chromosome 3 cells. We found that the expression levels 
of c-Myc and of c-Myc target genes were not affected, indicating that the putative hTERT 
repressor on chromosome 3 is unlikely to affect hTERT expression via alteration of c-Myc or 
one of its co-regulators. We also tested whether Notch is a regulator of hTERT, since Notch 
and hTERT expression correlates in embryonic cells and in some cancers. Over-expression of 
Notch1IC modulated hTERT RNA levels in telomerase positive but not in telomerase 
negative cells, suggesting that Notch may be a regulator of hTERT. Though we identified 
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putative binding sites for an effector of Notch, CBF1, in hTERT gene, we have not yet 
evidence for a direct interaction of Notch1 with the hTERT gene.  
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RESUME 
Les télomères sont formés par un complexe d’ADN et de protéines qui protègent les 
extrémités des chromosomes des cellules eukaryotes. L’ADN télomérique est synthétisé 
spécifiquement par la télomérase, une ribonucléoprotéine constituée d’un ARN et de plusieurs 
sous-unités protéiques dont une transciptase inverse, appelée hTERT chez l’humain. Chez 
l’humain, l’activité de la télomérase est détectée dans les cellules germinales, dans les 
lymphocytes activés et dans 85 % des lignées cellulaires dérivées de tumeurs, ces cellules 
sont appelées télomérase positives. Au contraire, la majorité des cellules somatiques sont 
télomérase négatives. Par conséquent, les télomères de la majorité des cellules différenciées 
raccourcissent à chaque division cellulaire et ce phénomène est probablement une cause de la 
sénescence cellulaire. La surexpression artificielle de hTERT dans les cellules télomérase 
négatives est suffisante pour induire l’activité de la télomérase, rallonger leurs télomères et 
leur permettre une prolifération infinie. Par ailleurs, le profil d’expression de l'ARNm de 
hTERT est fortement correllé à l’activité de la télomérase. Ces résultats indiquent que 
l’expression de l’ARNm de hTERT est le facteur limitant de l’activité de la télomérase. 
Afin de comprendre comment l’expression de hTERT est régulée, nous avons déterminé 
par RT-PCR la quantité d’ARNm de hTERT dans des cellules télomérase positives et 
négatives. Dans des cellules telomérase positives, nous avons mesuré 0.2 à 6 molécules par 
cellule d’ARNm matures de hTERT et détecté de l’ARN immature de hTERT dans leurs 
noyaux. Par contre, dans des cellules télomérase négatives, le niveau de l’ARN n’est pas 
détectable (<0.004 molécules/cellule). Ces résultats suggèrent une régulation de hTERT au 
niveau de sa transcription.  
Dans le but de caractériser les éléments régulateurs de hTERT, nous avons développé 
un système de gène rapporteur pour lequel une faible efficacité de transfection n’est pas 
limitante. Dans ces rapporteurs, l’expression de la GFP a été placée sous le controle de 
fragments de hTERT situés en 5’ du site d’initiation de la traduction. Nous avons testé ces 
rapporteurs dans des cellules télomérase positives et négatives. De ces experiences, il en 
resulte qu’une région de 7.4 kb en 5’ de hTERT ne suffit pas à mimer l’expression endogène 
de hTERT dans certaines cellules.  
Comme c-Myc est un régulateur connu de hTERT, nous avons étudié son rôle lors de la 
répression de hTERT par un répresseur putatif codé par le chromosome 3. Par RT-PCR, nous 
avons montré que l’expression de c-Myc et de ses gènes cibles ne sont pas modifiés par le 
transfert du chromosome 3 dans ces cellules, indiquant que le répresseur putatif codé par le 
chromosome 3 ne diminue pas le taux d’ARNm de hTERT via c-Myc. Nous avons aussi testé 
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si Notch pourrait contrôler l’espression de hTERT. La cascade Notch affecte la différentiation 
et, de plus, Notch est surexprimé dans certains cancers. Nous avons montré que la 
surexpression de la partie intracellulaire de Notch (Notch1IC) module l’expression  de 
hTERT dans des cellules télomérase positives. Aucun effet sur la transcription de hTERT n’a 
été détecté dans des cellules télomérase négatives. Bien que nous ayons identifié au niveau du 
locus hTERT des sites de liaison probables pour CBF1, un effecteur de Notch, nous n’avons 
pas pour l’instant de preuve d’une interaction directe de Notch avec hTERT. 
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1 INTRODUCTION 
 
1.1 TELOMERE STRUCTURE AND FUNCTIONS 
Telomeres are DNA-protein complexes at the ends of linear eukaryotic chromosomes 
(reviewed in (McEachern et al., 2000) (Fig. 1). Mammalian telomeric DNA consists of 
tandem arrays of double-stranded TTAGGG repeats, which end with a single-stranded G-rich 
3’overhang. The length of the double-stranded repeat ranges from a few to more than 10 kb 
(Collins, 2000), whereas the length of the 3’overhang corresponds to 150 to 200 nucleotides 
(Makarov et al., 1997; McElligott and Wellinger, 1997; Wright et al., 1997). The 
conventional DNA replication machinery cannot replicate the 3’overhang because the 
parental CA-rich strand is recessed and cannot function as template. Telomerase, a 
ribonucleoprotein, can solve the end replication problem by balancing telomere loss with 
addition of telomeric repeats to the ends of chromosomes (Lingner and Cech, 1998; Nugent 
and Lundblad, 1998).  
 
Figure 1: Telomere lengths of metaphase spread of human T cells transduced with a control (A) or a 
hTERT containing vector (B). Telomeres were probed with a specific PNA-probe (yellow), DNA was stained by 
DAPI (blue). Arrows indicate telomere loss. The pictures were kindly provided by Nathalie Rufer. 
 
Telomeres serve different functions. First telomeres protect the end of linear 
chromosomes from degradation and unwanted fusion events (McClintock, 1941; van Steensel 
et al., 1998). Damaged telomeres will be subject to DNA repair, and undergo end-to-end 
fusion, which causes dicentric chromosomes that impair the next cell divisions. Second they 
specifically position chromosomes at the nuclear periphery in yeast (Gotta et al., 1996), while 
in mammalian cells the telomeres form nuclear matrix-associated complexes at dispersed sites 
troughout the nucleus (Ludérus et al., 1996). Third, in budding yeast and in mammals, 
telomeres seem to control transcription of genes located close to them (Baur et al., 2001; 
A. B.
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Gottschling et al., 1990). This phenomenon is referred as telomere position effect or telomere 
silencing. Finally telomere shortening may limit the replicative potential of normal human 
cells providing a powerful tumor-suppressive mechanism (Wright and Shay, 2001).  
 
1.2 MAMMALIAN TELOMERIC PROTEINS 
Double-stranded telomeric repeats are bound directly by at least two proteins, TRF1 
(Chong et al., 1995; Smith and de Lange, 1997) and TRF2 (Bilaud et al., 1997; Broccoli et 
al., 1997) (TTAGGG repeat binding factor 1 and 2). TRF2 proteins stabilize telomeres by 
creating the so-called T loop (Griffith et al., 1999) (Fig. 2A). In this structure the 3’overhang 
folds back and is thought to invade the duplex of double-stranded telomeric repeats. In this 
way the telomeric end is sequestered and may be protected from inappropriate repair activities 
and end-to-end fusion and from telomerase elongation (Fig. 2B) (Broccoli et al., 1997). Over-
expression of wild-type TRF1 reduces telomere length and over-expression of dominant-
negative TRF1 increases telomere length (van Steensel and de Lange, 1997), suggesting a role 
for TRF1 in controlling telomere length homeostasis. TRF1 is also implicated in maintenance 
of the mitotic checkpoint in response to DNA damage and it is involved in the mitotic spindle 
checkpoint. TRF1, also called Pin2 (Shen et al., 1997), was also identified as an ATM kinase 
substrate (Kishi and Lu, 2001; Nakamura et al., 2001). A number of interacting partners of 
TRF1 have been discovered: PinX1 (Zhou and Lu, 2001), TIN2 (Kim et al., 1999) and 
Tankyrase 1 and 2 (Kaminker et al., 2001; Smith et al., 1998). Among them TIN2 and PinX1 
appear to function as positive regulators of TRF1-dependent pairing of telomeric repeats (Kim 
et al., 1999; Zhou and Lu, 2001). Tankyrase 1 ADP-ribosylates TRF1 in vitro thus reducing 
its binding affinity for telomeric DNA (Smith et al., 1998). Over-expression of tankyrase 1 
results in telomere elongation in telomerase positive cells (Cook et al., 2002). TRF2 may not 
only be a negative regulator of telomere length as TRF1 but also function to protect 
telomeres. Over-expression of dominant negative TRF2 induces loss of the single-stranded 
telomeric 3’ overhang leading to end-to-end fusion and ATM/p53 dependent apoptosis or 
cellular senescence (Karlseder et al., 1999; van Steensel et al., 1998). A human ortholog of 
the yeast telomeric protein Rap1p is recruited to telomeres by TRF2 (Li et al., 2000). Its 
function remains unknown. 
During the last couple of years proteins involved in DNA repair were also detected at 
telomeres. Some interact with TRF1 (Dunham et al., 2000; Hsu et al., 1999) or TRF2 (Zhu et 
al., 2000). For example a small fraction of RAD50, MRE11 and the Nijmegen breakage 
syndrome protein (NBS1), which are components of the double strand repair machinery 
(DSB), are associated with TRF2 in HeLa cells. 
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Figure 2: T-loop structure in mammalian cells. A telomeric DNA from mouse liver was isolated by size 
fractionation following psoralen/UV treatment of nuclei, deproteinization, and restriction cleavage. The DNA 
was spread on air-buffer interface with cytochrome c protein followed by rotary shadowcasting with platinum-
paladium. The T-Loop contains around 20 kb of DNA. B Proposed formation and functions of T-loop. (from 
(Griffith et al., 1999). 
 
Interestingly, NBS1 interacts with TRF2 at telomeres specifically in S phase of the cell 
cycle, suggesting a role for NBS1 in telomere replication (Zhu et al., 2000). Loss of Ku, 
which is also involved in non homologous end-joining (NHEJ), or its associated DNA protein 
kinase (DNA-PKcs), leads to end-to-end telomeric fusions and enhanced chromosomal 
instability in mammalian and yeast cells (Bailey et al., 1999; Difilippantonio et al., 2000; 
Gravel et al., 1998; Nugent et al., 1998; Polotnianka et al., 1998). These results indicate a 
possible role of Ku in telomere capping (Bertuch and Lundblad, 1998). Recently, it was 
shown that only leading-to-leading-strand end fusions occur in TRF2 dominant-negative 
mutants and DNA-PKcs deficient mouse cells (Bailey et al., 2001), suggesting different 
requirements for TRF2 and DNAPKcs in capping of lagging and leading strand after 
replication. Conventional DNA replication is predicted to give rise to leading strand 
telomeres, which are blunt ended, and to lagging strand telomeres that have a 3’G-rich single-
stranded overhang. Both types of ends may be processed further perhaps by degradation of the 
C-rich strand or by the 3’exonuclease activity of the MRE11/RAD50/NBS1 complex to allow 
the action of telomerase (Makarov et al., 1997; Wellinger et al., 1996; Zhu et al., 2000).  
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1.3 THE TELOMERASE RIBONUCLEOPROTEIN 
Telomerase is the enzyme required for the addition of telomeric repeats to the ends of 
linear chromosomes. It consists of a reverse transcriptase, TERT that carries its own template 
in the form of an RNA moiety, TER (Feng et al., 1995). TERT has homology to viral reverse 
transcriptases (RT) (Lingner et al., 1997) (Fig. 3) and contains the conserved RT motifs and a 
telomerase specific motif.  
 
Figure 3: Reverse transcriptase (RT) domains of HIV as a model for TERT RT domains. As in most 
polymerases, the active site is present in a cleft, the structure of which is compared to a half-open right hand with 
fingers, palm and thumb.The red and green motifs contain the critical asparagine residues for activity. (Reprinted 
with permission from (Nakamura et al., 1997).  
 
The RNA moiety includes the template sequence for synthesis of telomeres. These two 
components are both necessary and sufficient to mediate telomerase activity in vitro, although 
a variety of additional molecules regulate its in vivo activity (see below). TERC has a 
conserved secondary structure found in ciliates and vertebrates (Chen et al., 2000; Lingner et 
al., 1994), including a pseudoknot, which is essential for activity and stable assembly with 
TERT (Gilley and Blackburn, 1999) and a H/ACA box (Mitchell et al., 1999). The H/ACA 
motif of telomerase RNA is essential for the accumulation of TERC and for telomerase 
activity in vivo (Mitchell and Collins, 2000). The members of the H/ACA snoRNA family 
function in ribosomal RNA maturation, specifying sites of pseudouridine modification or 
processing (Ganot et al., 1997). The human dyskerin, that was previously cloned as the 
mutated gene responsible for X-linked dyskeratosis (DKC) is a component of H/ACA 
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snoRNPs and stabilizes TERC (Mitchell et al., 1999; Vulliamy et al., 2001). Other proteins 
were found to be associated with TERC such as Staufen (Le et al., 2000), L22 (Le et al., 
2000) and hnRNP A1 (Fiset and Chabot, 2001; Labranche et al., 1998). The roles of these 
proteins remain unclear. It is also unclear whether the assembly of the telomerase holoenzyme 
occurs in the cytoplasm or in the nucleus. Two proteins, p23 and hsp90, are involved in the 
assembly of active telomerase (Holt et al., 1999). They remain associated with the telomerase 
complex (Forsythe et al., 2001).  
Recent experiments indicate that telomerase functions as a dimer (Beattie et al., 2001; 
Wenz et al., 2001). In one study telomerase activity was reconstituted in cells expressing two 
different inactive fragments of hTERT suggesting a role of hTERT dimerization in the 
generation of active telomerase (Beattie et al., 2001). The second study established that the 
active reconstituted holoenzyme has a molecular weight that is consistent with a dimer of both 
hTERT and hTERC and that the isolated complexes contain two hTERC molecules. They also 
showed that a reconstituted enzyme that consisted of a heterodimer of wild-type and mutant 
hTERC had a dramatic reduction in telomerase activity (Wenz et al., 2001), indicating that the 
two molecules of hTERC cooperate for extension of telomeres 3’ends. Several potential roles 
for hTERT/hTERC multimerization have been proposed. They include enhancement of 
telomerase processivity and formation of a binding interface that recognizes telomeric DNA. 
 
1.4 RECRUITMENT OF TELOMERASE 
Molecular mechanisms underlying the recruitment of telomerase to the chromosome 
ends, and the coordination of DNA replication with telomerase action are currently being 
investigated. In budding yeast, at least five genes are necessary for the in vivo activity of 
telomerase: EST1-3, TLC1 and CDC13 (Lundblad and Szostak, 1989). Cdc13p is a single-
stranded G rich DNA binding protein that is required to protect telomere ends from 
degradation and to recruit the telomerase complex to chromosome ends (Evans and Lundblad, 
2000). Recently, in human, a single-stranded G-rich binding protein, Pot1 (for protection of 
telomeres) that may serve the same function was identified (Baumann and Cech, 2001). Yeast 
Est1p interacts specifically with the single-stranded telomeric DNA overhang (Nugent et al., 
1998). Est1p and Est3p were shown to be associated with the telomerase holoenzyme 
(Hughes et al., 2000) and Est1p recruits in cooperation with cdc13p telomerase to the end of 
the chromosome (Evans and Lundblad, 1999).  
Recent work in several systems support the hypothesis that telomeres may switch 
between at least two states: capped and uncapped (Blackburn, 2000). The capped state would 
preserve telomeres and thereby chromosome integrity, whereas the uncapped state would 
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allow the access of enzymes to telomeres for restoring its cap. The cap function may be 
fulfilled by T-loops in mammalian cells (Fig. 2B) or Pot1p, binding to free G-rich 
3’overhangs. The uncapped state may permit the elongation by telomerase while preventing 
end-joining reactions at telomeres.  
 
1.5 TELOMERE MAINTENANCE IN HUMAN 
In human embryonic cells telomerase activity is detected in germ-line, blastocysts and 
up to 16 to 20 weeks old fetal tissues (Ulaner and Giudice, 1997; Wright et al., 1996). In adult 
humans the enzyme is present in cells of the germline that give rise to mature gametes, as well 
as in at least some stem cell populations and in activated lymphocytes but not in differentiated 
cells (Chiu et al., 1996; Wright et al., 1996). Thus most somatic human cells lack the 
telomerase enzyme (Kim et al., 1994) and their telomeres shrink with each replication cycle 
by approximately 30 to 100 bp (Counter et al., 1992; Harley et al., 1990; Huffman et al., 
2000). Since short telomeres induce cellular senescence in tissue culture (Bodnar et al., 1998), 
it has been proposed that telomere shortening may limit the replicative potential of normal 
cells providing a powerful tumor-suppressive mechanism (Wright and Shay, 2001). In 
contrast to somatic cells 85% of human tumor-derived immortal cells have detectable 
telomerase activity (Kim et al., 1994). In a minority of tumor cells an alternative non-
telomerase dependent mechanism (ALT) is responsible for telomere stabilization (Bryan et 
al., 1997). In several somatic cell types ectopic expression of human TERT (hTERT) is 
sufficient to induce in vitro and in vivo telomerase activity, to elongate their telomeres and to 
extend the life span of these cells (Bodnar et al., 1998; Morales et al., 1999; Vaziri and 
Benchimol, 1998; Yang et al., 1999). Moreover among the number of telomerase-positive and 
negative cells so far examined, the expression of hTERT mRNA correlates with the presence 
of telomerase activity (Ducrest et al., 2001; Meyerson et al., 1997; Nakamura et al., 1997). 
This indicates that expression of hTERT is the limiting step for the induction of telomerase 
activity in most cells.  
 
1.6 GOAL OF THE THESIS 
In my thesis, I have addressed the question of how hTERT expression is regulated. In 
chapter 2, we present the possible models for controlling hTERT expression and review the 
different hTERT regulators that have been identified so far. To elucidate the mechanism 
controlling hTERT expression we used three different approaches. First, we attempted to 
characterize the regulatory elements of hTERT gene using a reporter assay. As described in 
Chapter 3, we set up a GFP reporter system that can be analyzed at the single-cell level by 
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flow cytometry. With this system, we can reliably measure the activity of weak promoters 
even in cells transfected with low efficiency. Based on this technique, we analyzed hTERT-
GFP reporter constructs containing 5’flanking region of the hTERT gene in telomerase 
positive and negative cells. In chapter 4, we showed that a 7.4 kb fragment upstream of the 
translation start site of hTERT, placed in a reporter construct, is not sufficient to mimic 
endogenous hTERT gene in some cells. Second, we measured levels of different hTERT 
RNAs by quantitative RT-PCR (Chapter 4). This study led us to the conclusion that hTERT 
RNA is controlled at the level of gene transcription, but, however, failed to exclude that 
regulation involves changes in the efficiency of nuclear processing of primary transcripts. 
Third, we tested a candidate regulator of hTERT for its effect on hTERT RNA expression 
(Chapter 5). We reasoned that in most carcinomas hTERT expression may not be due to the 
reactivation of the hTERT gene but reflects the advantage, during tumor progression of cells 
in which differentiation is partially blocked and hence hTERT expression maintained 
(Chapter 2). Notch may be a good candidate to modulate hTERT expression, since Notch1 
controls cell differentiation in embryonic cells and its abnormal expression was detected in 
some cancers. We found that in some telomerase positive cells Notch1IC modulated hTERT 
expression, but in telomerase negative cells no effect could be detected.  
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2 REGULATION OF THE HUMAN TELOMERASE REVERSE 
TRANSCRIPTASE GENE1 
 
2.1 ABSTRACT 
Most somatic human cells lack telomerase activity because they do not express the 
telomerase reverse transcriptase (hTERT) gene. Conversely, most cancer cells express hTERT 
and are telomerase positive. For most tumors it is not clear whether hTERT expression is due 
to their origin from telomerase positive stem cells or to reactivation of the gene during 
tumorigenesis. Telomerase negative cells lack detectable cytoplasmic and nuclear hTERT 
transcripts; in telomerase positive cells 0.2 to 6 mRNA molecules/cell can be detected. This 
suggests that expression is regulated by changes in the rate of hTERT gene transcription. In 
tumor cell lines hTERT expression behaves like a recessive trait, indicating that lack of 
expression in normal cells is due to one or several repressors. Studies with monochromosomal 
hybrids indicate that several chromosomes may code for such repressors. A number of 
transcription factors, tumor suppressors, cell cycle inhibitors, cell fate determining molecules, 
hormone receptors and viral proteins have been implicated in the control of hTERT 
expression; but these studies have not yet provided a clear explanation for the tumor specific 
expression of the hTERT gene, and the cis-acting elements which are the targets of repression 
in normal cells still have to be identified. 
 
2.2 INTRODUCTION 
Telomerase is the enzyme required for the addition of telomeric repeats to the ends of linear 
chromosomes. It consists of a reverse transcriptase, TERT that carries its own template in the 
form of an RNA moiety, TER. In vitro this complex can add telomeric repeats to artificial 
substrates. Its activity in vivo depends on other components some of which probably control 
the access of the enzyme to chromatid ends (Evans and Lundblad, 2000). In the absence of 
telomerase the telomeres of normal cells shorten by about 50 nt per cell population doubling 
(Counter et al., 1992; Harley et al., 1990; Huffman et al., 2000). In adult humans the enzyme 
is present in the germ line stem cells that give rise to mature gametes as well as in at least 
certain stem cell populations and in activated lymphocytes, but not in differentiated cells 
(Chiu et al., 1996; Wright et al., 1996). In the absence of telomerase activity human somatic 
epithelial cells and fibroblasts can undergo approximately 50 to 60 population doublings 
                                                 
1
 This review was published in Oncogene 2002, 21, 541-552 with the following authors: Anne-Lyse Ducrest, 
Henrietta Szutorisz, Joachim Lingner and Markus Nabholz. The main contribution of Henrietta Szutorisz is the 
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before telomere shortening leads to replicative senescence (see e.g.(Bodnar et al., 1998). In 
rodents TERT expression is maintained during differentiation, and cellular senescence is not 
due to absence of telomerase (Russo et al., 1998). Observations on TER-deficient mice 
indicate that the enzyme is not required for the development and normal life span of 
laboratory mice in early generations (Blasco et al., 1997). However, propagation of mTERC -
/- mice for three or more generations leads to extensive telomere shortening and affected 
development and function of multiple tissues (Lee et al., 1998). In several human cell types 
ectopic expression of human TERT (hTERT) is sufficient to induce in vitro and in vivo 
telomerase activity and to «immortalize» the cells, indicating that none of the other 
components is limiting (Bodnar et al., 1998; Morales et al., 1999; Vaziri and Benchimol, 
1998; Yang et al., 1999). 
There is a striking correlation between the presence of hTERT mRNA and telomerase 
activity (see e.g.(Ducrest et al., 2001), and this has been taken to suggest that hTERT 
expression is regulated through changes in the rate of transcription, but direct evidence for 
this is scarce (see below). Post-transcriptional regulation of hTERT expression through 
alternative splicing has been observed during human development (Ulaner et al., 2001), and 
there have been claims that posttranslational modifications can affect TERT activity (Kang et 
al., 1999; Kharbanda et al., 2000; Liu et al., 2001; Yu et al., 2001), but the role of such 
mechanisms in tumor specific telomerase expression is, as yet, quite unclear. The finding that 
most tumors express hTERT and telomerase activity (Kim et al., 1994), and that in vitro 
transformation of telomerase negative human cells requires activation of hTERT expression 
(Hahn et al., 1999) indicates that maintenance of telomeres is required for the unlimited 
proliferative potential of tumor cells. This conclusion is supported by the finding that 
telomerase negative in vitro transformed cells maintain telomeres through an alternative 
(ALT) pathway that is based on somatic recombination (Bryan et al., 1995; Dunham et al., 
2000). 
For oncology the importance of understanding the mechanisms that control hTERT 
expression in tumors is two-fold; on the one hand, it may lead to the discovery of targets for 
new cancer therapies, and on the other hand it might provide cis-acting regulatory elements 
that could contribute to tumor targeting of tumoricidal genes or viruses. Thus, it is not 
surprising that there have been a large number of groups that have tried to dissect the 
mechanisms that control hTERT expression. In this review we discuss this work, limiting 
ourselves to efforts to elucidate the mechanisms regulating hTERT mRNA levels, and try to 
                                                                                                                                                        
preparation of Table 1 and she tested the role of TCF in hTERT regulation. She is currently investigating the 
cromatin structure of the hTERT gene by nuclease hypersensitivity assay and by ChIP. 
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explain why so far it has provided few if any conclusive answers that would be helpful to 
oncologists.  
 
2.3 MAINTENANCE OF EXPRESSION OR ACTIVATION OF THE hTERT 
GENE? 
Human skin or lung fibroblasts do not express hTERT and senesce after 50 to 60 
population doublings. Ectopic expression of hTERT renders these as well as endothelial cells 
«immortal» without inducing any changes in their karyotype or other signs of transformation 
(Bodnar et al., 1998; Jiang et al., 1999; Morales et al., 1999; Vaziri et al., 1999; Yang et al., 
1999). There is no report of spontaneous immortalization of normal fibroblasts, but SV40 
infection, by blocking the p53 and p16 dependent pathways that arrest cells when they reach 
senescence, extends their life span (see (Duncan and Reddel, 1997) for review). These cells 
eventually hit a «crisis» during which almost all cells die with the exception of a few 
transformed survivors that either maintain their telomeres by the ALT pathway (see (Reddel, 
1997) for review) or express hTERT. In this case there is no doubt that hTERT expression has 
been reactivated. Whether this occurs in tumors is much less clear (for a discussion of this 
issue see (Greaves, 1996; Shay and Wright, 1996). There is evidence that some, perhaps most, 
tumors are derived from cells that have already gained their first alterations towards malignant 
transformation before undergoing differentiation, close to a stem-cell like stage when hTERT 
may still have been expressed. The clearest case can probably be made for colorectal 
carcinoma. Colorectal adenomas are derived from crypt cells some of which can express 
hTERT, as detected by in situ hybridisation (Kolquist et al., 1998). Many adenomas 
themselves contain hTERT expressing cells but a proportion of them lack detectable 
telomerase activity (Yan et al., 2001). This may reflect the fact that most adenoma cells 
undergo differentiation and eventually die, while a small variable number of undifferentiated 
cells ensure the survival of the tumor. These may be the hTERT positive cells detected in situ. 
Thus, in most carcinomas hTERT expression may not be due to reactivation of the 
hTERT gene but to the fact that the cells which maintain the tumor are prevented from 
differentiating and maintained in a stage at which their normal counterparts still express 
hTERT. The finding that the frequency of telomerase negative sarcomas is higher than that of 
carcinomas (Yan et al., 1999) suggests that sarcomas might be more frequently derived from 
hTERT negative cells for which there is no preferential choice of the mechanism through 
which they stabilize chromosome ends (Carroll et al., 1999). 
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2.4 WHY DO TUMOR CELLS NEED TELOMERASE? 
Telomeres are structures that prevent the ends of a linear chromosome to be mistaken 
for a double strand break (Godhino Ferreira and Promisel Cooper, 2001; McClintock, 1941; 
van Steensel et al., 1998). If these structures are disrupted, the cell attempts to repair the break 
and, in doing so, generates fusions between the telomeres of different chromatids. Fusions 
occur when the number of telomeric repeats drops below a critical level, in cells which lack 
telomerase (Blasco et al., 1997; Hackett et al., 2001) and do not express an ALT pathway. 
Thus, most tumor cells need telomerase to maintain telomeres sufficiently long to keep the 
incidence of chromosome fusions low. However, telomere attrition to a level at which 
telomeres cease to protect chromosome ends requires 50 to 60 cell doublings, and it is not 
clear whether the cells in a tumor have indeed undergone that many divisions, even taking 
into account cell loss due to differentiation and death. It seems important to consider 
alternative reasons for the hTERT expression by most tumors. One explanation may lie in the 
chromosomal instability that characterizes most cancer cells (Parshad and Sanford, 2001) (see 
(Sen, 2000) for review). At least some of this instability arises from the breakage and fusion 
of chromosomes. Indeed, breakage is involved in the amplification of oncogenes or genes 
conferring drug resistance, through breakage-fusion-bridge cycles (Coquelle et al., 1997; 
Coquelle et al., 1998)2. Although chromosome breaks can provide the cellular substrate for 
the selection of more aggressive tumor cells, they will also give rise to non-viable cells. One 
way to keep these processes in check is through de novo addition, by telomerase, of telomeres 
to the ends of broken chromosomes (Friebe et al., 2001; Hande et al., 1998; Varley et al., 
2000). This would mean that premalignant cells, which express hTERT, have an advantage 
over the others not only when cells have undergone more than 50 to 60 divisions, but at a 
much earlier stage when chromosome breakage becomes frequent.  
 
2.5 IS hTERT EXPRESSION REGULATED BY CHANGES IN THE LEVEL 
OF GENE TRANSCRIPTION? 
As pointed out above there is a very strong correlation between telomerase expression 
and the presence of detectable hTERT mRNA (Meyerson et al., 1997; Nakamura et al., 1997). 
We have compared the numbers of hTERT molecules per cell, determined by quantitative 
RT-PCR, in a number of cell lines from different tissue origins (Ducrest et al., 2001). In all 
                                                 
2
  Telomere loss itself can lead to chromosomal instability, and experiments with telomerase-deficient mice 
show that this correlates with a very strong increase in the incidence of carcinomas. What the contribution 
of telomere loss to genome instability in the evolution of human tumors is remains to be analysed. The 
answer to this question depends, in part, on what fraction of tumors is derived from telomerase positive 
stem cells. 
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telomerase positive cells hTERT transcripts are detectable but rare (0.2 to 6/cell) whereas no 
transcripts (<0.004/cell) could be detected in telomerase negative cells. This correlation has 
been widely assumed to reflect regulation of hTERT expression via control of the rate of 
transcription. But it is equally compatible with regulation of transcript processing or changes 
in the mRNA half-life. Although a considerable number of transcription factors have been 
implicated in the control of hTERT expression (see below), direct evidence that hTERT gene 
transcription is regulated is scarce. Specifically it is unclear whether the tumor specific 
expression of hTERT is controlled at the level of transcription. The finding that activation of a 
c-Myc-estrogen receptor ligand binding domain fusion can increase hTERT mRNA levels in 
the absence of protein synthesis shows that ectopic c-Myc can indeed directly stimulate 
transcription of the gene (Greenberg et al., 1999; Oh et al., 2000; Wu et al., 1999). We will 
discuss the biological role of c-Myc in hTERT regulation below. 
The classical assay detecting changes in the rate of gene transcription, run-on nuclear 
experiments which measure the average loading of RNA-polymerase molecules on the gene, 
has been reported for one leukemia cell line (U937) (Gunes et al., 2000). This study indicated 
that in these blood cells hTERT is regulated at the level of transcription rather than RNA 
stability. We have made attempts to obtain similar evidence for a tumor cell line derived from 
fibrosarcoma (HT1080) that contains relatively high numbers of hTERT transcripts among the 
cell lines screened by us, and have been unable to detect run-on transcription signal above 
background. The probable reason for this failure is that the rate of transcription is too low in 
HT1080 cells to be detectable by this approach. Comparing the levels of spliced cytoplasmic 
mRNA with that of intron-containing nuclear transcripts in different telomerase positive and 
negative cell lines, we observed that telomerase negative cells did not contain detectable 
levels (< 0.004 molecules/cell) of either cytoplasmic mRNA or nuclear transcripts, whereas 
telomerase positive cells contained both transcript forms. These results clearly suggest that 
hTERT mRNA levels are indeed controlled at the level of gene transcription, but they do not 
exclude that regulation involves changes in the efficiency of nuclear processing of primary 
transcripts.  
 
2.6 POSSIBLE MODELS OF hTERT REGULATION 
In a sense hTERT behaves like a protooncogene; abnormal maintenance or reactivation 
of expression contributes to tumorigenesis. Thus, one would expect that genomic changes that 
can lead to improper expression of protooncogenes, such as translocations that include the 
regulatory regions, would also be found in the hTERT genes of tumors.  
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Indeed, there is one report (Horikawa and Barrett, 2001) suggesting that the integration 
of the hepatitis B viral genome into the 5’flanking region of the hTERT gene might induce its 
expression in a hepatocellular carcinoma. But so far, there is no other evidence indicating a 
role of cis-acting gene rearrangements in the activation or maintenance of hTERT expression 
in tumors. We have found no evidence for rearrangements in the 5’flanking region and the 
5’half of the gene (-10 to +25 kb) screening a number of cell lines of divers origin. The 
second intron of the hTERT gene contains a meiotically unstable minisatellite with several 
putative binding sites for c-Myc (Szutorisz et al., 2001; Wu et al., 1999). Size rearrangements 
of that minisatellite are not required for telomerase expression in colon carcinomas (Szutorisz 
et al., 2001). In 31 of 33 colon carcinomas that were heterozygous for the polymorphic 
minisatellite the 1:1 ratio of hTERT alleles was maintained, indicating that there had been no 
gene amplification in these tumors. In the two remaining tumors there was a change compared 
to normal tissue from the same patient, compatible with amplification of one hTERT allele. 
Amplification of the hTERT gene was also detected in another study, in 20% of primary 
tumors and 40% human cancer derived cell lines (Zhang et al., 2000). Amplification may be 
the result of selection for higher expression of an active hTERT gene. It might also lead to the 
expression of an inactive gene as a consequence of the genomic rearrangements that give rise 
to amplification, or through titration of a gene specific repressor.  
Another modification that might affect hTERT expression is DNA methylation. Turning 
off the expression of tumor suppressor genes or genes involved in DNA repair, through 
methylation of their promoter, can contribute to carcinogenesis. Comparison of the 
methylation status of the hTERT promoter in telomerase positive and negative cells has not 
provided any compelling clues that this type of modification controls tumor specific hTERT 
expression (Dessain et al., 2000; Devereux et al., 1999). 
 hTERT expression due to cis-acting gene rearrangements should behave like a 
dominant trait. Dominant expression would also be likely if demethylation of the hTERT 
promoter were the mechanism through which hTERT expression is activated in tumors. 
However, so far no cross in which hTERT expression is dominant has been reported. On the 
other hand there is a number of tumor lines in which hTERT expression behaves like a 
recessive trait; expression is extinguished in hybrids with telomerase negative cells or by 
transfer of single chromosome from a normal cell (Table 1) (Bryan et al., 1995; Cuthbert et 
al., 1999; Horikawa et al., 1998; Nishimoto et al., 2001). This suggests that hTERT 
expression in normal cells is repressed by a mechanism, which is no longer functional in 
tumors. The simplest model that accounts for these observations is that hTERT transcription 
is under the control of a repressor, absent in cancer cells, that acts via a cis-acting element in 
the hTERT gene. Note, that the repressor may not itself be a sequence specific DNA-binding 
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protein, but could be a co-repressor interacting with a transcription factor. The data are 
equally compatible with a model according to which the repressor controls a gene coding for 
an obligatory activator of hTERT transcription, and so on. The finding that single normal 
chromosomes can repress hTERT expression in tumors has led to attempts to clone the genes 
coding for such repressors, by positional cloning (see next section). 
 
2.7 HOW MANY hTERT REPRESSORS ARE THERE? 
Table 1 lists the chromosome transfer experiments that have addressed the question of 
hTERT regulation. The data summarized are not homogeneous, and different studies testing 
the same chromosome have not always used the same chromosome donor cells. It should also 
be kept in mind that a normal chromosome may undergo changes in the donor cells. This 
might explain that chromosome 6 represses hTERT in the cervical carcinoma line SiHa in one 
study but fails to do so in another. Alternatively, the different result may reflect changes in the 
cell line. Given these limitations the studies listed in Table 1 strongly suggest that there is no 
single chromosome that represses hTERT expression in all cells. Chromosome 3, e. g. 
represses hTERT expression in several but not all of the recipient lines tested. This is not 
unexpected; even if there were a single molecular complex that is responsible for the 
repression of the hTERT gene in normal cells, mutations in both copies of any gene coding 
for a component of the complex should lead to inactivation of the repressor and expression of 
hTERT. It would certainly be interesting to determine whether a large-scale chromosome 
screen would reveal patterns, e.g. consistent repression of hTERT expression by chromosome 
6 in HPV16-transformed tumors. The available data do not permit to detect such patterns. 
Transfer of chromosomes from irradiated donor cells can be used for attempts to positionally 
clone a putative hTERT repressor gene. The chromosome for which this approach is most 
advanced is chromosome 3. Upon introduction of a normal chromosome 3, two renal, one 
breast, and one cervical carcinoma line ceased to express hTERT. Two groups using either a 
renal carcinoma (Tanaka et al., 1998) or a breast cancer derived line (Cuthbert et al., 1999) as 
recipients have narrowed the region that confers repression to 3p14.2-21.1. This region 
overlaps with a segment of chromosome 3 that undergoes frequent LOH in breast cancer 
(Maitra et al., 2001). LOH and deletions of smaller parts of 3p have been identified in breast, 
cervix, colon, lung, and renal carcinomas (Kok et al., 1997).  
In a single study both chromosome 3 and 4 have been found to shut off hTERT 
expression in HeLa cells. This suggests multiple independent pathways of repression. Since 
mutations affecting a repressive pathway are recessive, activation of hTERT expression 
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through such mutations would be expected to be an extremely rare event. It might explain 
why spontaneous immortalization of normal fibroblasts has never been observed. 
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TABLE 1 Effect of normal human chromosomes on hTERT expression in telomerase positive cell lines 
Recipient cell line Phenotype of hybrids Transferred 
chromosome Name Cell typea Telomerase 
activity 
hTERT 
mRNA 
Other 
chromosomes 
testedb 
Source of chromosomesc Reference 
TE85 osteosarcoma + nd   (Koi et al., 1989) (Hensler et al., 1994) 
# 1 
B16-F10 mouse melanoma + nd   (Koi et al., 1989) (Oshimura and Barrett, 1997) 
SiHa cervical carcinoma + nd 3, 6, 7, 9, 11, 12  (Koi et al., 1989) (Tanaka et al., 1999) 
# 2 
B16-F10 mouse melanoma + nd   (Koi et al., 1989) (Oshimura and Barrett, 1997) 
RCC23 renal cell carcinoma - - 7, 11  (Koi et al., 1989) (Horikawa et al., 1998; Tanaka et al., 1999) 
KC12 renal cell carcinoma in VHL - nd 11  (Koi et al., 1989) (Tanaka et al., 1998) 
21NT breast carcinoma - - 8, 12, 20 
chr 3, 8, 20: (Cuthbert et al., 
1995);  
chr 12: (Ning et al., 1992) 
(Cuthbert et al., 1999) 
HeLa cervical carcinoma - nd 6, 11 chr 3: MCH 922.5; chr 6: MCH 226; chr 11: MCH 556 (Backsch et al., 2001) 
# 3 
TS1 lung adenocarcinoma + nd   (Koi et al., 1989) (Ohmura et al., 1995) 
# 4 HeLa cervical carcinoma - nd 6, 11 chr 4: HA(4)A9; chr 6: MCH 226;  
chr 11: MCH 556 (Backsch et al., 2001) 
FK16A HPV16-immortalised keratinocyte - - 11 
chr 6: (Cuthbert et al., 1995);  
chr 11: (Koi et al., 1989) (Steenbergen et al., 2001) 
# 6 
SiHa cervical carcinoma - - 11 chr 6: (Cuthbert et al., 1995);  
chr 11: (Koi et al., 1989) (Steenbergen et al., 2001) 
CC1 choriocarcinoma + nd 1, 2, 6, 9, 11 (Koi et al., 1989) (Tanaka et al., 1999) # 7 MeT5A SV40-transformed mesothelial cell - -  (Koi et al., 1989) (Nakabayashi et al., 1999) 
# 10 Li7HM hepatocellular carcinoma - - 2, 4, 5, 16 
chr 2, 4, 5, 10: (Kugoh et al., 
1999);  
chr 16: (Koi et al., 1989) 
(Nishimoto et al., 2001) 
# 11 JTC-32 bladder carcinoma + nd 7  (Koi et al., 1989) (Tanaka et al., 1999) 
# 17 BP1-E immortalized breast epithelial cell - nd 11  (Koi et al., 1989) (Yang et al., 1999) 
nd, not determined. a Cells are of human origin, unless mentioned otherwise. b Chromosomes that did not affect cell immortality (when the chromosome indicated in the 
first column had no effect on telomerase) or telomerase activity. In bold chromosomes which repress telomerase activity or hTERT expression in another cell line.  
c Reference to the panel of chromosome donor cells used. 
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2.8 OTHER APPROACHES TO STUDY REGULATION OF hTERT 
EXPRESSION 
2.8.1 Screening candidate molecules 
The mapping and cloning of genes on normal chromosomes that shut off hTERT 
expression in tumor cells is one approach towards the elucidation of the regulation of hTERT 
expression. Other, complementary approaches consist in (1) the testing of candidate 
molecules for their effect on the expression of the endogenous hTERT gene, or (2) attempts to 
identify the cis-acting elements in the hTERT gene that control its expression. The former 
approach is based on guesses as to what molecules might be involved in hTERT regulation 
which can be tested either through the ectopic expression of such putative positive regulators 
in hTERT negative cells, or through the expression of dominant negative version of such 
molecules in hTERT expressing cells. The latter is a better approach that can provide 
informative data even if the results are negative. Candidates include molecules whose 
abnormal expression in tumor cells prevents their differentiation, such as c-Myc, TCF or 
Notch. The second approach aims at the identification of cis-acting regulatory sequences in or 
near the hTERT gene through experiments using reporter gene constructs and including in 
vitro assays for DNA binding proteins, nuclease hypersensitivity, in vivo footprinting assays 
and ChromatinIP.  
Numerous molecules, including transcription factors, regulators of differentiation and 
the cell cycle and proteins of viruses implicated in tumorigenesis, have been proposed to 
regulate hTERT expression. We have attempted to summarize the most relevant findings in 
Table 2 and Fig. 1, without being exhaustive in our literature citations. Many studies were 
based on the ectopic expression of positive regulators. The interpretation of such experiments 
is often difficult. An example is provided by the studies on the effect of c-Myc on hTERT 
expression. The published data show that overexpression of c-Myc can increase the level of 
hTERT mRNA in B-cell lines or induces its appearance in fibroblasts. This effect does not 
depend on protein synthesis and is therefore likely to be due to a direct action of c-Myc 
protein on the hTERT gene (Greenberg et al., 1999; Oh et al., 2000; Wu et al., 1999). Mad, 
the antagonist of c-Myc was shown to be a potential repressor of hTERT. Mad was a 
candidate repressor identified in a gene screen for hTERT regulators (Oh et al., 2000), and a 
rise in endogenous Mad RNA and protein levels was inversely correlated with hTERT RNA 
levels (Gunes et al., 2000; Oh et al., 2000; Xu et al., 2001). Finally, while c-Myc protein was 
found associated with the hTERT gene in vivo in telomerase positive promyelocytic leukemia 
HL60 cells as determined in chromatin immunoprecipitation assays (Xu et al., 2001), 
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differentiation of these cells by DMSO led to downregulation of hTERT, loss of association 
with c-Myc and binding of the c-Myc antagonist Mad1. These results show that the c-
Myc/Mad regulatory network can regulate hTERT expression, but the role of this network in 
tumor specific hTERT expression is not yet clear. Deregulation of the c-Myc/Mad balance is 
unlikely to be sufficient for the activation of the hTERT gene in cancers, for several reasons: 
(1) In most cases overexpression of c-Myc is expected to behave like a dominant trait in 
somatic cell crosses, unlike of what has been observed for hTERT expression. (2) In 
exponentially growing fibroblasts c-Myc is expressed at lower levels than in tumor derived 
cell lines (Gewin and Galloway, 2001; Kyo et al., 2000; Oh et al., 2000), and declines even 
further when fibroblasts are serum deprived. Restimulation with serum induces a transient, 
high level of c-Myc and downregulation of Mad (Grandori et al., 2000; Obaya et al., 1999), 
but there is no evidence that this change is sufficient to induce hTERT expression. (3) 
Overexpression of HPV16 E7, which is important for immortalization of keratinocytes, 
induces high level of c-Myc protein but is unable to activate telomerase expression (Gewin 
and Galloway, 2001; Veldman et al., 2001). (4) In the breast cancer derived cell line 21NT 
chromosome 3 transfer leads to immediate repression of the hTERT gene but expression of c-
Myc, Mad1 and c-Myc target genes remained unchanged (Ducrest et al., 2001). Therefore, the 
putative repressor on chromosome 3 does not regulate hTERT through c-Myc or one of its 
coregulators. In conclusion, it seems likely that normal changes in the c-Myc/Mad ratio 
control hTERT transcription in cells in which the gene is not “closed” by one or several 
repressors, but that the levels of c-Myc in most tumors are not high enough to overcome 
repression. One obvious possibility is that in normal cells competent to express the gene c-
Myc links hTERT expression to the proliferative status of the cell. Other genes involved in 
the control of cell cycle progression have been suggested to repress hTERT expression such 
as p53, p16, p21 and E2F-1 (Table 2 and Fig.1). However the effect of these genes on hTERT 
expression remains ambiguous. The best case can be made for p53, which was shown to 
downregulate hTERT expression. This effect seems to be independent of p53 induced cell 
cycle arrest and apoptosis (Kanaya et al., 2000; Kusumoto et al., 1999; Xu et al., 2000). 
Another case in which hTERT can be regulated independently of differentiation and/or 
growth inhibition is the acute promyelocytic leukemia cell line NB4-R1, in which treatment 
with retinoic acid dowregulates hTERT without inducing maturation (Pendino et al., 2001).  
As suggested above hTERT expression in most carcinomas may not be due to a 
reactivation of the hTERT gene but reflect the advantage, during tumor progression of cells in 
which differentiation is partially or completely blocked and, as a consequence, hTERT 
expression maintained. This view would predict that pathways which control cell 
differentiation and which are frequently deregulated in cancer, such as the Notch and the Wnt 
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pathways may be implicated in hTERT regulation. We have found that in the breast cancer 
cell line, 21NT, overexpression of the intracellular part of the Notch 1 protein increases the 
levels of hTERT transcripts as well as of HES-1, a known Notch1 target (A.D.; unpublished 
data). Similarly, arguing that TCF activity may be required for hTERT expression in colon 
carcinoma cells we have determined the levels of hTERT mRNA in four colon carcinoma cell 
lines carrying tetracycline inducible constructs coding for dominant negative version of TCF1 
or TCF4. These lines were prepared by Marc van de Wetering in the laboratory of Hans 
Clevers. Tetracycline treatment of such cells leads to a significant down-regulation of a 
number of TCF target genes expressed in colon carcinomas, but had no effect on hTERT 
transcript levels which were comparable to that in control cells from the same tumors lacking 
the dominant negative TCF constructs. These results quite strongly argue that TCF does not 
play a role, direct or indirect, in controlling hTERT expression in colon carcinomas. 
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Figure 1: Schematic representation of the potential cis-acting regulatory elements in the first 1000 bp 
upstream of the translation start site of the hTERT gene. Rectangles represent putative activator binding sites 
(except for Mad), ovals represent putative repressor binding sites. 
 
In estrogen-targeted tissues, such as endometrium (Kyo et al., 1997; Saito et al., 1997; 
Takakura et al., 1999), prostate (Meeker et al., 1996) and epithelial cells with high renewal 
potential (Bednarek et al., 1998) estrogen-responsive cells may be more prone to form tumors 
(Hilakivi-Clarke, 2000; Liehr, 2000) because they are telomerase positive. Estrogen was 
shown to activate hTERT promoter constructs through estrogen responsive elements (ERE) in 
the hTERT 5’flanking region. This activation was dependent on the presence of estrogen 
receptor-α. Genomic footprinting indicated that one ERE element, 950 bp upstream of the 
translation start site, is occupied in vivo in cells expressing, but not in cells lacking, the 
estrogen-receptor-α (Misiti et al., 2000). This is in agreement with the finding that tamoxifen, 
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an antagonist of estrogen, reduces telomerase activity in the breast cancer cell line MCF-7 
cells (Aldous et al., 1999). Since in this line estrogen also increases c-Myc levels (Kyo et al., 
1999), c-Myc may contribute to activation of hTERT transcription.  
2.8.2 On the use of hTERT-reporter constructs 
There have been many attempts to identify cis-acting regulatory elements in the hTERT 
gene through the use of reporter constructs (see Table 2 and Fig. 1). The main a priori 
limitation of this approach is that it makes assumptions on the location of the regulatory 
elements, which can be at considerable distance, 3’ or 5’ of the gene, or in introns. 
Furthermore, certain regulatory elements might not work outside of their endogenous context. 
Therefore the use of the basic reporter construct should be validated in experiments testing 
whether it contains the cis-acting elements controlling the expression of the endogenous gene, 
e.g. by transfection into appropriate cell lines. Claims that hTERT reporter expression reflects 
that of the endogenous gene have been based on the comparison of reporter expression in 
normal cells with that in various cell lines. However, in vitro transformed or tumor cells differ 
from normal cells in many respects that can affect the rate of gene transcription in ways, 
which are unrelated to gene specific regulation. To solve this problem we (Ducrest et al., 
2001) have compared the expression of a series of reporter constructs containing the hTERT 
promoter and up to 7.5 kb of 5' flanking region in two SV40 transformed fibroblast lines. One 
of these is telomerase positive, whereas the other uses the ALT pathway and contains no 
detectable hTERT transcripts. All reporter constructs were more strongly expressed in either 
line than in normal fibroblasts, and there were no significant differences between the activity 
of any of the reporters in the telomerase positive and the ALT line. Knight et al also have 
reported hTERT promoter activity in an ALT cell line SUSM-1 when using another reporter 
containing 1.7 kb of the hTERT flanking region (Knight et al., 2001). Even more strikingly, 
we observed no differences in the expression of the same hTERT reporters when we 
compared them in a breast carcinoma line and its derivatives in which transfer of a single 
normal chromosome 3 has reduced hTERT mRNA by at least 30 fold, to undetectable levels 
(Ducrest et al., 2001). Thus, by these stringent criteria the validation of hTERT reporters 
containing the longest 5' flanking segment tested so far has completely failed, and the 
significance of the results obtained with similar constructs in other cells (see table 2) has to be 
assessed in the light of this failure.  
Of course, this does not mean that regulatory sites identified in constructs expression of 
which does not mimic that of the endogenous gene have no role in the regulation of the latter, 
but without strong additional evidence such identifications provide only very weak 
arguments. The finding that an element identified in this way indeed binds a transcription 
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factor that might be implicated in the regulation in vitro adds very little weight to the 
argument. Strong evidence that binding of a transcription factor to a putative regulatory site 
plays a role in the control of gene expression requires demonstration that the factor occupies 
the site in vivo, most convincingly by ChromatinIP with antibodies against the putative 
regulator. But even such experiments cannot, by themselves, prove that the transcription 
factor in question controls the difference in hTERT gene expression in normal versus tumor 
cells. It is quite possible that certain transcription factor binding sites are indeed occupied in 
hTERT expressing but not in telomerase negative cells, and that occupation is required for 
hTERT transcription. But occupancy may reflect that fact that in cells competent to express 
the gene these sites are “open” i.e. accessible to the transcription factor, due to chromatin 
alterations that depend on other proteins which bind elsewhere and are higher up in the 
hierarchy of control.  
2.8.3 Screening for changes in hTERT chromatin 
The search for differences between the conformation of the chromatin containing the 
hTERT gene in hTERT expressing and non-expressing cells provides a complementary 
approach to the identification of cis-acting elements. The classical method used is to screen 
the locus of interest for sites with differential sensitivity to nucleases such as DNaseI or 
Micrococcal nuclease (MNase). In numerous instances the activity of a regulatory element 
correlates with the presence of a nuclease hypersensitive site or region at or near the element. 
Compared to ChromatinIP, this type of analysis has the advantage that it can be applied to 
very large genomic segments without previous assumption about the possible localization of 
regulatory elements, but it has the disadvantage that there are no strict rules describing the 
relationship between, say, transcription factor occupancy of a regulatory site and its nuclease 
sensitivity. Thus, lack of nuclease sensitive sites in a segment does not exclude that it plays 
regulatory role. Application of the technique to the hTERT gene has to face another 
uncertainty; as discussed above the rate of hTERT gene transcription is probably very low 
(Ducrest et al., 2001), and even in a cloned hTERT positive cell line not all cells may 
transcribe the gene at a given moment. This may – or may not – mean that important 
regulatory elements in the gene are not always occupied, and that the corresponding nuclease 
hypersensitive sites are invisible in the background of chromatin from non-transcribed genes. 
Nevertheless, comparison of different telomerase positive and negative cell lines points to the 
existence of two nuclease sensitive sites in the second intron of telomerase expressing cells, 
and the significance of these sites has been validated by the stringent type of criteria outlined 
above for reporter construct analysis (H.S., manuscript in preparation). It remains to be seen 
whether these sites are the primary targets of the molecules that induce hTERT transcription 
Regulation of hTERT expression 
- 29 - 
 
in tumors, or whether these chromatin alterations are the downstream consequence of the 
activity of cis-acting elements elsewhere in the gene. 
 
2.9 OUTLOOK 
One impression that emerges from this review is that in spite of considerable efforts by 
many groups, our understanding of the mechanisms that are responsible for the tumor specific 
expression of the human TERT gene is still very poor. This raises two questions. On the one 
hand one has to ask what new or at least modified approaches are most likely to be more 
successful than the attempts carried out so far, and on the other one is lead to consider the 
possibility that the models which determine the choice of methods are inappropriate or wrong.  
At this time it seems that the approach which is most likely to provide insight into the 
regulation of hTERT expression is the positional cloning of genes on chromosomes that shut 
off hTERT expression upon microcell mediated transfer into tumor cell lines. However, it is 
by no means certain that such genes once they have been identified provide immediate clues 
as to the mechanisms through which they affect hTERT expression, and to unravel these 
mechanisms it would certainly be extremely useful if not essential to have a reporter system 
which does mimic the expression pattern of the endogenous hTERT gene according to the 
stringent criteria outlined above. To build such a system may require the use of much larger 
genomic segments as they are available, e.g., in BAC clones. BAC clones containing the 
hTERT gene are accessible but their sequence is not yet publicly available. Reporter 
constructs based on BAC clones of other genes have been successfully used for the study of 
regulation, but the technical investment required is not trivial, and one needs to take into 
account the risk that the experiments fail because of the very low level of hTERT 
transcription.  
If a reporter system that faithfully reproduces the tumor-specific regulation of the 
hTERT gene were available, it might be informative to determine its expression pattern in 
transgenic mice. As pointed out earlier, the TERT of the mouse (mTERT) and other rodents is 
not shut off in differentiated somatic cells (Russo et al., 1998). This difference between 
rodents and man may reflect changes in the cis-acting elements or in the expression of 
transacting factors. If hTERT gene expression in the mouse resembles that in man this would 
argue strongly that repression of hTERT expression during differentiation is due to 
differences in cis-acting elements only. What evolutionary pressure may have led to the 
somatic repression of hTERT expression? A simple idea is that this may be related to the 
species’ life-span; in species that reach reproductive age late, repression of telomerase activity 
which provides an important barrier to malignant disease should confer a stronger selective 
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advantage than in species with a short life-span.  Not enough species have been analyzed to 
allow evaluation of this hypothesis.  
There are several aspects of hTERT expression that are puzzling and apparently 
contradictory. The finding that immortalization of normal fibroblasts by spontaneous 
activation of hTERT expression has never been observed, and that it is a rare event even after 
viral transformation, is hard to reconcile with the finding that it is quite easy to turn on 
hTERT expression in normal cells, through overexpression of c-Myc or treatment with an 
inhibitor of histone deacetylases (Cong and Bacchetti, 2000; Takakura et al., 2001; Xu et al., 
2001). The indication, from monochromosomal tumor cell hybrids, that there are different 
genetic loci which can shut down hTERT expression, suggests that perhaps repression of 
hTERT is due to diffuse mechanisms that affect the chromatin structure in and around the 
hTERT gene, rather than to a few well defined target sites of sequence specific repressors or 
activators. In this context it may be relevant that the hTERT gene is close to the telomere of 
the short arm of chromosome 5. This raises the possibility that the gene is subject to telomeric 
repression which has recently been shown to exist in human cells (Baur et al., 2001). The 
precise position of the hTERT gene has not yet been determined (Bryce et al., 2000). It will 
be interesting to test whether expression of other genes close to the telomere of chromosome 
5p correlates with that of hTERT. 
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Table 2 Molecules implicated in the regulation of hTERT expression 
Proposed regulator                Endogenous gene Reporter constructs 
Cells 
Name Type1 
hTERT 
Activator/ 
Repressor Name Cell type  
Telome- 
rase 
Tech- 
niques2 mRNA3 Chromatin4 
Transfected 
 cells 
Gene 
segment 
analysed5 
Putative cis-
acting 
elements6 
In vitro 
 DNA 
binding 
 assays7 
References 
E2F-1 TF R SCC25 tongue carcinoma + WT down     -1453/-1 
-251/-247 
and/or 
-175/-171 
BS: REP Crowe et al., 2001 
EREB8 
CB33 EBV-immortalized B lymphocytes + WT up   293T 
-800/-1 
intron 2 mE1-2, mE2 BS: MT Wu et al., 1999 
HL60 promyeleucytic leukemia + DMSO down ChIP-296/+20       BS: MT, S Xu et al., 2001 
HMEC breast epithelial cells - WT up           Wang et al., 1998 
IMR908 embryonic lung fibroblasts - WT up   NIH3T3 -2500/-1 -35/-2   Greenberg et al., 1999 
           
C33A9 
ME180 
SiHa 
NHK 
-260/-1 mE1-2, mE1, 
mE2 BS: REP, S Kyo et al., 2000 
WI388 embryonic lung fibroblasts - WT up   293 -4000/-1 mE1-2 BS: REP Oh et al., 2000 
c-Myc TF A 
WI38 embryonic lung fibroblasts - WT up   HeLa -300/-1   BS: MT Oh et al., 1999b 
           C33A9,10 -260/-1 mE1-2   Kyo et al., 2000 
WI388 embryonic lung fibroblast - WT down   WI38 293T -260/-1 mE1-2 BS: REP Oh et al., 2000 
U937 monoblastoid leukemia + TPA down     -2500/-1 mE111   Gunes et al., 2000 
Mad TF R 
HL60 promyeleucytic leukemia + DMSO down ChIP-296/+20         Xu et al., 2001 
MZF-212 TF R C33A SiHa cervical carcinoma +   ?
13
     -1450/-1 
-763/-757, 
-696/-689, 
-620/-614, 
-591/-58414 
BS: REP 
 -763/-757 Fujimoto et al., 2000 
SiHa cervical carcinoma + WT down     -3410/-1 -110/-1   Kanaya et al., 2000 
PaCa-2 pancreatic cancer + WT down           Kusumoto et al., 1999 p53 TF, TS R 
BL41 Burkitt's lymphoma + MT15  down16   HeLa -4000/-1 -330/-1 BS: MT,  S (SP1)17 Xu et al., 2000 
SP1 TF A            
C33A9 
ME180 
SiHa 
-260/-1 
mGC1: ne, 
single mGC2 to 
mGC5, 
mGC1-5 
  Kyo et al., 2000 
TCF TF no effect 
DLD1 
LS174 
HCT116 
colon carcinoma + DN18 ne           
H.S., H. Clevers,  
M. van de Wetering, 
unpublished 
WT119 TF, TS R 293 
adenovirus type 5 transformed 
embryonic kidney + WT down   
293 
HeLa -1000/-1 -358/350
20
 BS: REP Oh et al., 1999a 
?,  binds to 
MT box TF A            
HEY21 
SKOV-3 
OVCAR-3 
-5870/-1 -31/-24 BS: REP Braunstein et al., 2001 
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Proposed regulator                     Endogenous gene Reporter constructs 
Cells  
Name Type1 
hTERT 
Activator/ 
Repressor Name Cell type 
Telome 
rase 
Tech- 
niques2 mRNA3 Chromatin4 
Transfected 
cells 
Gene 
segment 
analysed5 
Putative 
cis-acting 
elements6 
In vitro 
 DNA 
binding 
 assays7 
References 
HL60 promyeleucytic leukemia + DMSO, TSA up ChIP-296/+20         Xu et al., 2001 
HRCE renal cortical epithelial - TSA up     -3420/-1 mE1-2:ne 
mGC1-5   Takakura et al., 2001 HDAC22 ChME R 
BJ 
MRC5 
WI38 
primary fibroblast - TSA up   HA123 -4080/-1 
-260/-1 
but 
mE1-2:ne 
  
Cong & Bacchetti, 
2000 
p16INK4A CKI, TS R TSU-PR1 prostate carcinoma + ACT down     -1450/-1 mE1-224   Kitagawa et al., 2000 
PaCa-2 pancreatic cancer + WT ne           Kusumoto et al., 1999 
BL41 Burkitt's lymphoma + AS, 
mimosine2 ne           Xu et al., 2000 p21WAF1 CKI ? 
T47-D breast carcinoma -26 AS down27           Wang et al., 2000 
MCF-7 breast cancer + E2 up   
MCF-7 
SiHa29 
NHK29 
-3410/-1 mE1-230 
BS: MT,S 
-2754/-
2742 
Kyo et al., 1999 
LLO/LEA ovarian surface epithelial cells - E2 up           
OVCA-
43331 
MCF-731 
ovarian surface epithelium, 
 
breast cancer 
 
+ 
+ 
 
E2 
E2 
  
  
 
iv-949/-935 
iv-949/-935 
WOO29 
NIH3T329 -1000/-1 
-949/-935 
-330/-1: ne 
BS: REP 
  
ER28 HR A 
HeLa32 
MDA32 
cervical carcinoma 
breast cancer 
+ 
+ 
E2 
E2   
no footprint 
no footprint         
Misiti et al., 2000 
PR33 HR R T-47D breast carcinoma -26 WT + E2 up and down34     -3400/-1     Wang et al., 2000 
RAR35 HR R NB4 acute promyelocytic leukemia + ATRA down           Pendino et al., 2001 
Notch1 CFD A 21NT breast carcinoma + WT36 up           A.D., unpublished 
- WT, MT37 up38     -710/-1 mE1-2   Gewin & Galloway, 2001 
- WT up     -1180/-15 -185/-50   Veldman et al., 2001 HPV16 
E6 
  
  
VP 
  
  
A 
  
  
HFK 
  
  
foreskin keratinocytes 
  
  - WT up   HFK C33A 
-800/-18 
-260/-1 
mGC1-5, 
mE1-2:ne 
single mGC1 
to mGC5: ne 
  Oh et al., 2001 
ne or up           Oh et al., 2001 HPV16 
E7 VP ? HFK foreskin keratinocytes - WT ne           Gewin & Galloway, 2001; Veldman et al., 2001 
KSHV-
LANA39 VP A 293 
adenovirus type 5 transformed  
embryonic kidney + WT up   BJAB -1720/-50 -185/-50 
BS: MT, S 
(SP1) Knight et al., 2001 
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1Transcription factor (TF), tumor suppressor (TS), chromatin modifying enzyme (ChME), cyclin dependent kinase inhibitor (CKI), hormone receptor (HR), cell fate determining protein (CFD), viral protein (VP). 2 
Ectopic expression of wildtype (WT), dominant negative (DN) or mutant (MT) protein; antisense (AS); treatment with phorbol ester (TPA), trichostatin A (TSA), DMSO or estrogen (E2), 5-aza-cytidine (ACT), all-
trans-retinoic acid (ATRA). 3No effect (ne), increase (up) or decrease (down). 4Positions of chromatin IP (ChIP) or in vivo footprint (iv). 5Position +1 corresponds to translation start site. The major transcription 
start site lies between -55 and -77 (Horikawa et al., 1999; Takakura et al., 1999; Wick et al., 1999). Indicated is the longest fragment tested. 6Two putative c-Myc/Max or Mad/Max binding sites (E boxes) and 5 
putative SP1 binding sites (GC boxes) were identified and mutated in several studies. E boxes: E1: -34/-29; E2: -242/-237. mE1, mE2: Mutation of one of the sites in one reporter. mE1-2: Mutation of both E boxes 
in the same reporter construct.  GC boxes are GC1: -84/-79; GC2: -113/-105; GC3: -133/-124; GC4: -165/-159; GC5: -187/-179.   mGC1-5: Mutation of all five GC boxes in the same reporter construct. mGC1, 
mGC2, ....: Mutation of individual site. No effect: ne. 7Bandshift (BS) assays; mutant probes or competition with mutant oligonucleotides (MT); effect of mutations on reporter expression (REP); supershift 
experiments (S). 8EREB, IMR90 and WI38 cells contain a Myc-estrogen receptor fusion protein (Myc-ER). The cells were treated with 4-hydroxy-tamoxifen (4-OH-T) and cycloheximide (CX). 9C33A, ME180, 
SiHa: cervical carcinoma cell lines. NHK: primary keratinocytes. 10Ectopically expressing Mad and Max. 11Ectopic expression of Mad1. 12Myeloid-specific zinc finger protein 2. 13Telomerase activity reduced in 
cells ectopically expressing MZF-2.. 14All sites mutated in the same reporter construct. 15Cell line expressing p53 ts mutant. 16Effect not through p21. 17Extracts from SL2 insect cells ectopically expressing SP1 and 
p53. 18Stable transfectants inducibly expressing dominant negative versions of TCF-1 or TCF-4. 19Wilms' tumor 1. 20No effect in HeLa. 21Ovarian carcinomas. Effect only in HEY cells. 22Histone deacetylase. 
23SV40 T transformed embryonic kidney. 24p16 reduces c-Myc expression. 25In BL41-p53ts, at permissive temperature. 26Expression dependent on E2 or progesterone. 27Decrease of progesterone dependent 
expression. 28Estrogen receptor. 29Cells ectopically expressing estrogen receptor α (ER- α) were treated with estrogen. 30E2 increases c-Myc expression in MCF-7. 31Estrogen receptor α-positive. 32Estrogen 
receptor α-negative. 33Progesterone receptor. 34Progesterone induces transient expression (12 h) and reduces the estrogen mediated increase (48 h). Both effects are blocked by an inhibitor of MEK. 35Retinoic acid 
receptor. 36Constitutively active intracellular portion of Notch1. 37MT: HPV16E6-8S/9A/10T, defective in p53 degradation. 38Effect correlates with E6 binding to E6AP. 39Kaposi's sarcoma associated herpesvirus 
latency-associated nuclear antigen. 
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3  DETECTION OF PROMOTER ACTIVITY BY FLOW 
CYTOMETRIC ANALYSIS OF GFP REPORTER EXPRESSION3 
 
3.1 ABSTRACT 
Low efficiency of transfection is often the limiting factor for acquiring conclusive data 
in reporter assays. It is especially difficult to efficiently transfect and characterize promoters 
in primary human cells. To overcome this problem we have developed a system in which 
reporter gene expression is quantified by flow cytometry. In this system GFP reporter 
constructs are co-transfected with a reference plasmid that codes for the mouse cell surface 
antigen Thy-1.1 and serves to determine transfection efficiency. Comparison of mean GFP 
expression of the total transfected cell population with the activity of an analogous luciferase 
reporter showed that the sensitivity of the two reporter systems is similar. However, because 
GFP expression can be analyzed at the single-cell level and in the same cells the expression of 
the reference plasmid can be monitored by two-color fluorescence, the GFP reporter system is 
in fact more sensitive, particularly in cells which can only be transfected with a low 
efficiency.  
 
3.2 INTRODUCTION 
Understanding the mechanisms controlling transcription of a gene requires the 
identification and characterization of its cis-acting regulatory elements. In mammalian cells 
transient transfection of plasmids in which a reporter gene is expressed under the control of a 
fragment of the gene to be analyzed is widely used for this purpose. Following transfer of the 
reporter construct into cells, the expression of the reporter gene is monitored by measuring the 
amount of reporter mRNA, of the reporter protein itself or its enzymatic activity. The 
commonly used reporters include chloramphenicol acetyltransferase (CAT), β-galactosidase, 
firefly or renilla luciferase, alkaline phosphatase (AP) or green fluorescent protein (GFP). 
GFP protein is unique in that the GFP fluorophore spontaneously forms intracellularly 
without added cofactors (Heim et al., 1994). Therefore, the emitted fluorescence intensity 
provides a direct readout of GFP expression (Cheng et al., 1996) that can be measured at the 
single-cell level without any processing steps. Flow cytometry analysis of GFP was used for 
monitoring expression of inducible reporters (Anderson et al., 1996) and for detecting time 
dependent IκB degradation (Li et al., 1999). Recently the combination of enhanced intensity 
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of GFP fluorescence (Yang et al., 1996) with destabilization of the GFP protein (Li et al., 
1998) improved the detection reliability of GFP fluorophore principally in induction studies.  
Most efforts to map cis-acting regulatory elements have made use of cell lines that can be 
transiently transfected with a sufficiently high efficiency to permit the use of the standard 
reporter systems. Since cell lines are never completely normal, the results obtained are always 
subject to some reservations. The most important of these could be avoided if normal cells 
were used as recipients. But the transfection efficiency of most normal cell types is not 
sufficiently high, even when more recently developed transfection reagents are used. Here we 
describe a system that overcomes this problem by permitting the quantification of the 
expression of reporter constructs as well as that of a reference plasmid at the single-cell level. 
With this approach we can reliably measure the activity of weak promoters in primary human 
lung fibroblasts. 
                                                                                                                                                        
3
 This chapter is in press in Nucleic Acid Research Online as a method article with the same title and the 
following authors: Anne-Lyse Ducrest, Mario Amacker, Joachim Lingner and Markus Nabholz. Mario 
Amacker constructed the GFP reporters used in this study. 
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3.3 MATERIALS AND METHODS 
3.3.1 Cells 
Primary human embryonic lung fibroblasts (HLF, a generous gift of Urs Ziegler, 
University Hospital, Zürich), a fibrosarcoma-derived line (HT1080, kindly provided by Ian 
Kerr, ICRF, London) and Phoenix cells, packaging cells derived from the 293 cell line (a gift 
from a Garry Nolan, Stanford University, CA) were maintained in high glucose DMEM with 
10% fetal calf serum. 
3.3.2 Plasmids 
pSV2Thy-1.1 expresses the mouse Thy-1.1 allele under the control of the SV40 enhancer 
and early promoter (Wilson et al., 1990). The luciferase reporters pGL3 Basic, pGL3 
Promoter, pGL3 Promoter and Enhancer, pRL-SV40 were purchased from Promega. PRL-
SV40 contains the renilla gene under the control of the SV40 early promoter and enhancer. To 
generate the GFP reporter vectors pd2G (basic vector), pSVd2G (promoter vector) and 
pSVEd2G (promoter/enhancer vector), we replaced the HindIII/XbaI fragment containing the 
luciferase gene of pGL3 by the HindIII/XbaI fragment of pEGFP-N1 (Clontech) containing 
the EGFP gene. The GFP gene was destabilized by adding the degradation domain of MODC 
as described by Clontech (Li et al., 1998). The half-lives of the GFP and luciferase proteins 
were 2h and 3h, respectively (Li et al., 1998; Thompson et al., 1991).  
3.3.3 Transfections 
Transient transfections with calcium-phosphate precipitates were performed according to 
Jordan (Jordan et al., 1996). In the standard protocol, cells were co-transfected with 1 µg 
pSV2-Thy-1.1 as reference plasmid and 1 to 5 µg of GFP-reporters. To compare the GFP with 
the luciferase system, cells were co-transfected with 0.3 µg of pRL-SV40 and 1 to 5 µg of 
pGL3 promoter constructs. The total amount of plasmid DNA was kept constant (6 µg) by 
adding pUC19.  
3.3.4 Determination of reporter expression. 
Reporter expression was determined 40 h after transfection. For GFP and Thy-1.1 assays, 
cells were harvested by trypsinization, incubated for 30 min with a saturating concentration of 
allophycocyanin (APC) labeled anti-Thy-1.1 antibody III-5 (MacDonald et al., 1985), kindly 
prepared by Céline Maréchal, and washed once. We analyzed the cells on a FACScalibur 
microflow cytometer (Becton Dickinson, Franklin Lakes, NJ). Using forward and side scatter 
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parameters we eliminated dead cells and debris from the analysis. GFP was excited by an 
argon laser and fluorescence was detected using a 530/30 nm bandpass filter in the FL1 
channel. Allophycocyanin was excited by a red diode laser and fluorescence emission was 
detected using a 661/16 nm bandpass filter in the FL4 channel. For Dual luciferase-renilla 
assays, cells were lysed in the Passive Lysis Buffer (Promega). The assay was performed on a 
Luminometer (Lumac, Biocounter M2500, MWG) as described by Promega. 
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3.4 RESULTS AND DICUSSION 
3.4.1 Flow cytometry analysis of the GFP-reporter system. 
Our reporter system consists of two plasmids: a GFP reporter that is used to test 
regulatory role of segments of the gene to be analyzed, and a plasmid (pSV2Thy-1.1) that 
encodes the murine Thy-1.1 cell surface marker. This antigen is resistant to the trypsin 
concentrations used to detach the cells (data not shown) and its expression can be quantified 
by labeling the cells with allophycocyanin (APC) coupled to anti-Thy-1.1 antibody.  
Thy-1.1 expression is used to measure transfection efficiency. To determine whether 
GFP could be used as a reporter gene, we co-transfected GFP and pSV2-Thy-1.1 reporters 
into Phoenix cells and analyzed the GFP and Thy-1.1 expression by two-color flow cytometry 
40 hours after transfection. Forward and side scatter signals were used to restrict the analysis 
to viable cells. GFP fluorescence intensity (FL1, X-axis) was plotted on a log scale against the 
fluorescence intensity (FL4, Y-axis) due to APC-coupled anti-Thy-1.1 antibody (Fig. 1). 
Signal amplification was set so that background fluorescence of non-expressing cells was 
below 10 (3 for GFP and to 7 for Thy-1.1) (Fig. 1). Thus, for both reporter plasmids 1000 fold 
differences in expression levels of over background could be measured. Fig. 1 shows that the 
GFP and APC signals can be separated over the entire range of signal intensity. In preliminary 
experiments we used a phycoerythryn (PE) labeled anti-Thy-1 antibody, but we found that it 
was impossible to compensate completely for the spill-over of the GFP fluorescence into the 
FL2 channel used to detect the PE-signal. This problem could be avoided by switching to an 
APC-anti-Thy-1.1 conjugate.  
When co-transfected with both plasmids, most cells emit GFP and APC fluorescence; 
they appear in the upper right quadrant (Fig. 1). With lower amounts of pSVEd2G GFP 
positive cells were found preferentially among the population expressing high levels of Thy-
1.1. These results are expected for transfection with calcium-phosphate precipitates, but the 
percentage of cells expressing both plasmids was similar when other, liposome-based 
methods (Fugene 6 (Roche), Lipofectamin 2000 (GIBCO), Effectene (Qiagen)) were tested 
(data not shown). The distribution of APC fluorescence intensity is not influenced by co-
transfection of the GFP reporter into the same cells, indicating that the pSV2-Thy-1.1 
promoter activity was not affecting by pSVEd2G (Fig. 1, 3). Thus, there is no evidence for 
competition for transcription factors between the two SV40-based promoters.  
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Figure 1: Two-color flow cytometry analysis of GFP reporter expression. Density plots of phoenix cells 
transfected with pUC19 alone, pSV2Thy-1.1 alone, pSVEd2G alone, or co-transfected with pSVEd2G and 
pSV2Thy-1.1. Reporter expression was analyzed 40h later. GFP fluorescence (X-axis) and Thy-1.1 surface 
expression, detected by an APC-labeled anti-Thy-1 antibody (Y-axis), were analysed by two-color flow 
cytometry. The numbers in the quadrants indicate the percentages of viable cells expressing pSV2-Thy-1.1 
alone, pSVEd2G alone, or pSVEd2G and Thy-1.1. The mean GFP and APC fluorescence intensities of the entire 
cell populations are indicated on the right. 
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3.4.2 Comparison of GFP and luciferase reporter systems 
To directly compare the luciferase and GFP reporter systems expression vectors 
containing the same backbone but coding either for GFP (pSVd2G) or luciferase (pGL3-
Promoter) was transfected into the fibrosarcoma cell line HT1080. GFP and luciferase have 
similar half-lives of approximately 2 to 3 h (Li et al., 1998; Thompson et al., 1991). For the 
luciferase reporter assay, HT1080 cells were co-transfected with the firefly luciferase reporter 
pGL3-Promoter and pRL-SV40 as reference for transfection efficiency. pRL-SV40 contains 
the renilla gene under the control of the promoter and early enhancer of SV40, and is thus 
comparable to pSV2-Thy-1.1. 40 h after transfection cells were lysed and enzymatic activity 
measured using the dual luciferase assay (Promega). Background activity, measured in cells 
expressing only renilla luciferase, was subtracted from the firefly luciferase activity of each 
transfected sample. To normalize for transfection efficiency, this value was divided by the 
renilla luciferase value of the same sample. The values obtained from the flow cytometry 
analysis of cells co-transfected with pSVd2G and pSV2-Thy-1.1 were subjected to analogous 
operations, i.e. we subtracted from the arithmetic mean of GFP expression the background 
obtained with cells transfected only with pSV2-Thy-1.1. To normalize for transfection 
efficiency, this value was divided by the equivalent measure for Thy-1.1 expression in the 
same cells.  Because 3.3 times less renilla plasmid was used, the GFP/APC ratio was 
multiplied by 3.3 in the plot shown in figure 2. Reporter gene expression increased linearly 
and with the same rate when between one and 4 µg of pSVd2G or pGL3 Promoter were 
transfected (Fig. 2). Comparing of several experiments, we found that beyond 4 µg of plasmid 
the increase in reporter expression was no more a function of plasmid concentration using 
either system. These results indicate that in HT1080 cells the GFP system monitors promoter 
activity with a similar sensitivity as the dual luciferase system.  
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Figure 2: Comparison of GFP-Thy-1.1 and luciferase-renilla reporter systems. HT1080 were transfected 
with 1 to 5 µg of pSV2G (GFP) and 1 µg of pSV2Thy-1.1 or with 1 to 5 µg of pGL3 Promoter (Luciferase) and 
0.3 µg of pRL-SV40. The expression of pSVd2G and of pGL3 Promoter reporters (F), normalized to that of their 
respective control plasmids (pSV2Thy-1.1 and pRL-SV40) is plotted against the amount of plasmid (A) used for 
transfection. The regression lines and correlation coefficients obtained when 1 to 4 µg of plasmid DNA were 
used are: F=0.037A + 0.0022 (R2: 0.84); F=0.036A + 0.0049 (R2: 0.74) for pSVd2G and for pGL3 Promoter, 
respectively. 
 
3.4.3 Measuring reporter expression in cells transfected with low efficiency  
Flow cytometry allows quantification of reporter gene expression in every cell of the 
transfected population. When cells are co-transfected with a reference plasmid, such as 
pSV2Thy-1.1, analysis of reporter gene expression can be restricted to cells that express the 
reference plasmid and are therefore likely to have been successfully transfected also with the 
reporter plasmid. This is particularly useful when transfection efficiency is low. Only 5 to 
10% of HLF cells co-transfected with pSVEd2G and pSV2Thy-1.1, expressed the reference 
plasmid (Fig. 3), and the mean GFP fluorescence intensity of the entire population was close 
to background. When analysis of GFP expression was restricted to Thy-1.1 positive cells, 
mean GFP intensity was not only much higher but also directly proportional to the amount of 
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transfected pSVEd2G plasmid. As shown in Fig. 3, between one and 3 µg of pSVEd2G the 
increase in GFP fluorescence intensity was linearly related to the amount of transfected 
plasmid. Thus, the GFP reporter system allows the analysis of reporters even in cells with a 
very low transfection efficiency, provided enough cells are analyzed to accumulate 
statistically significant data.  
 
 
Figure 3: Analysis of cells (normal human lung fibroblasts) that cannot be transfected with high efficiency. 
From 50’000 to 100’000 cells of each sample were passed through the flow cytometer. The horizontal line 
separates the Thy-1.1 expressing cells from the negative cells. The numbers in the quadrants indicate the 
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percentages of viable cells expressing pSV2-Thy-1.1 alone, pSVEd2G alone, or pSVEd2G and Thy-1.1. The 
mean GFP and APC fluorescence intensities of the entire populations (all) and of the pSV2Thy-1.1 positive 
(Thy-1.1 +) cells are indicated on the right. 
 
 
 
In summary, our result show that the GFP-based reporter system described here has a 
similar sensitivity than the luciferase system (Fig. 2). The GFP reporter system can be used 
for monitoring transcription like an enzyme-based system. But, because GFP expression can 
be quantified by flow cytometry in single cells, the system allows monitoring of transfection 
efficiency as well as of heterogeneity of the levels of reporter expression (Fig. 1). We show 
that by restricting analysis of reporter expression to cells that express a reference plasmid, 
reporter expression can be reliably quantified even in normal cells that cannot be transfected 
with high efficiency. Since flow cytometry can be combined with cell sorting, the system has 
other interesting applications, e.g. in situations in which one wants to measure the effect of a 
transiently transfected plasmid on a resident cellular gene or on a co-transfected reporter.  
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4 REGULATION OF HUMAN TELOMERASE ACTIVITY: 
REPRESSION BY NORMAL CHROMOSOME 3 ABOLISHES 
NUCLEAR hTERT TRANSCRIPTS BUT DOES NOT AFFECT c-Myc 
ACTIVITY4 
 
4.1 ABSTRACT 
Telomerase is required for the complete replication of chromosomal ends. In tumors, 
the telomerase reverse transcriptase subunit (hTERT) is up-regulated thereby removing a 
critical barrier for unlimited cell proliferation. To understand more about hTERT regulation, 
we measured hTERT RNA levels by quantitative reverse transcriptase (RT)-PCR. 
Telomerase-positive cell lines were found to contain between 0.2 and 6 molecules of spliced 
hTERT RNA per cell, whereas in telomerase-negative cells the number of molecules was 
below the sensitivity of the assay (<0.004 molecules/cell). Intron-containing, immature 
hTERT RNA was observed only in nuclei of telomerase-positive cells suggesting that hTERT 
RNA levels are transcriptionally regulated. Microcell transfer of a normal chromosome 3 into 
the human breast carcinoma cell line (21NT) abolishes telomerase activity and induces 
senescence. Endogenous hTERT transcripts were undetectable in the nuclei of 21NT-
chromosome 3 hybrids, even in cells permanently expressing a transfected hTERT cDNA. 
However, chromosome 3 transfer did not affect the expression of GFP reporter constructs 
driven by up to 7.4 kb of non-coding DNA flanking the 5’ end of the hTERT gene. Because 
direct up-regulation of hTERT through c-Myc overexpression had previously been reported, 
we investigated whether chromosome 3 transfer affected c-Myc activity. An at least 30 fold 
reduction of immature intron-containing hTERT RNA was observed following the 
introduction of a normal chromosome 3, but expression levels of c-Myc, Mad1 and other c-
Myc target genes were unchanged. Our results suggest that telomerase is regulated primarily 
at the level of hTERT transcription by complex mechanisms involving regulatory elements 
distant from the 5’ flanking region, and that the putative hTERT repressor on chromosome 3 
does not regulate the expression of hTERT through c-Myc or one of its co-regulators. 
 
 
                                                 
4
 This chapter was published in Cancer Research, 2001, 61, 7594-7602. The authors are Anne-Lyse Ducrest, 
Mario Amacker, Yves Mathieu, Andrew Cuthbert, Deborah Trott, Robert Newbold, Markus Nabholz and 
Joachim Lingner. The main contribution of Mario Amacker is the construction of the hTERT GFP reporter 
constructs used in this study. Yves Mathieu started during his diploma work the setting of the real time RT-PCR. 
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4.2 INTRODUCTION 
 
Telomeres are specialized DNA-protein complexes at the end of eukaryotic 
chromosomes that protect chromosome ends from fusion and degradation (Blackburn, 2000; 
Counter et al., 1992; McClintock, 1941; van Steensel et al., 1998). The complete replication 
of telomeric DNA requires a specialized reverse transcriptase, telomerase (Lingner and Cech, 
1998; Nugent and Lundblad, 1998). Most normal somatic human cells lack this enzyme (Kim 
et al., 1994) and their telomeres shrink with each replication cycle by approximately 30 to 100 
bp (Counter et al., 1992; Harley et al., 1990; Huffman et al., 2000). Since short telomeres 
induce cellular senescence in tissue culture (Bodnar et al., 1998), it has been proposed that 
telomere shortening may limit the replicative potential of normal cells providing a powerful 
tumor-suppressive mechanism (Wright and Shay, 2001). Cells of the germline and certain 
stem cells, as well as 85% of tumor-derived immortal cells contain telomerase, and their 
telomere length is stabilized (Kim et al., 1994). In a minority of tumor cells, however, an 
alternative non-telomerase dependent mechanism (ALT) is responsible for telomere 
stabilization (Bryan et al., 1997). 
Telomerase is a ribonucleoprotein (RNP) enzyme that consists of an RNA moiety and 
several protein subunits. Of these, the RNA moiety and the catalytic subunit are essential for 
telomerase activity in vitro. The RNA subunit contains a short segment that serves as the 
template for telomeric repeat synthesis (Chen et al., 2000; Feng et al., 1995; Greider and 
Blackburn, 1989; Yu et al., 1990). The catalytic protein subunit (hTERT) is related 
structurally and functionally to reverse transcriptases (Harrington et al., 1997; Lingner et al., 
1997; Meyerson et al., 1997; Nakamura et al., 1997; Nakayama et al., 1998). Among the 
number of telomerase-positive and negative cells thus far examined, the presence of hTERT 
mRNA is related to the presence of telomerase activity (Meyerson et al., 1997; Nakamura et 
al., 1997). In contrast, the telomerase RNA subunit and other components implicated in 
telomere maintenance are present in both telomerase-positive and negative cells. Furthermore, 
ectopic expression of hTERT in telomerase-negative fibroblasts or endothelial cells is 
sufficient to restore telomerase activity and to stabilize telomere length (Bodnar et al., 1998; 
Vaziri and Benchimol, 1998; Yang et al., 1999), whereas over-expression of dominant 
negative mutants of hTERT in tumor cells can inhibit telomerase activity and induce growth 
arrest (Hahn et al., 1999; Zhang et al., 1999). 
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The mechanisms that control hTERT gene expression may involve transcriptional 
regulation, RNA stability, processing and/or export to the cytoplasm. To date a number of 
regulators of hTERT expression have been identified including the Wilms’ tumor suppressor 
gene (WT1) product that reduces hTERT RNA levels in 293 kidney cells (Oh et al., 1999). 
Retinoids were shown to down-regulate hTERT RNA in acute promyelocytic leukemia 
(Pendino et al., 2001). Several activators of hTERT expression have also been identified. 
Estrogen induces hTERT RNA in estrogen receptor-positive cells (Kyo et al., 1999; Misiti et 
al., 2000). The E6 oncoprotein of human papillomavirus type 16 induces telomerase activity 
in epithelial, but not in fibroblasts (Kiyono et al., 1998; Klingelhutz et al., 1996). c-Myc 
directly acts on the hTERT gene inducing hTERT expression (Greenberg et al., 1999; Wu et 
al., 1999), whereas the c-Myc antagonist Mad down-regulates its expression (Gunes et al., 
2000; Oh et al., 2000). hTERT regulation involves histone acetylation since treatment of 
telomerase negative cells with trichostatin A activates telomerase (Cong and Bacchetti, 2000). 
In cell hybridization experiments the telomerase negative state behaves like a dominant 
trait, given that hybrids between telomerase-positive and negative cells are telomerase 
negative (Bryan et al., 1995). Microcell transfer of human chromosomes 2, 7, 11 induced 
cellular senescence in some tumor-derived cells. However, telomere length and telomerase 
activity are retained in these cells, implying that several inducers of senescence function 
independently of telomerase (Tanaka et al., 1999). By microcell transfer of human 
chromosomes into breast and kidney tumor cell lines a factor that directly or indirectly down-
regulates telomerase activity has been mapped to a region on chromosome 3p (Cuthbert et al., 
1999; Horikawa et al., 1998; Tanaka et al., 1998). Recently, it was shown that transfer of 
human chromosome 6 into a HPV16-immortalized keratinocyte cell line (FK16A) and into a 
HPV16-containing cervical cancer cell line (SiHa) reduced hTERT RNA levels (Nishimoto et 
al., 2001). Similar results were obtained after introduction of a fragment of human 
chromosome 10p into hepatocellular carcinoma cells (Li7HM) (Steenbergen et al., 2001). It 
was also shown that transfer of human chromosomes 3 or 4 into HeLa cells abolished 
telomerase activity (Backsch et al., 2001). 
RNA processing has also been implicated in the regulation of hTERT. Several splice-
variants of hTERT RNA which encode enzymatically inactive telomerases are expressed 
during embryonic development and are also detectable in some immortalized cells (Kilian et 
al., 1997; Ulaner et al., 1998; Wick et al., 1999). 
In order to study hTERT expression we developed a quantitative RT-PCR assay and 
measured spliced and unspliced hTERT RNA levels in primary cells and immortal cell lines. 
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We found that low levels of hTERT RNA are expressed in tumor cells, and that the level of 
immature nuclear hTERT RNA correlates with telomerase activity, suggesting a regulation of 
hTERT RNA levels in the nucleus. In addition, we demonstrate that reporters containing up to 
7.4 kb of 5’flanking region do not faithfully mimic expression of the endogenous hTERT 
gene. We show that transfer of a normal chromosome 3 into the human breast cancer cell line 
21NT results in complete silencing of endogenous hTERT (indicated by an absence of 
immature nuclear hTERT RNA) even in cells that are rescued from senescence by ectopic 
expression of hTERT cDNA construct. Moreover we characterized the mechanism by which 
chromosome 3 represses hTERT RNA expression in the breast cancer cell line 21NT. We 
provide evidence that the repressor does not act on regulatory elements in the immediate 5’ 
flanking region of the gene, and is independent of c-Myc or its co-regulators. 
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4.3 MATERIALS AND METHODS 
4.3.1 Cells 
Human embryonic lung fibroblasts (HLF, passage 6) were a gift from Urs Ziegler, 
Institute of Anatomy, University of Zuerich. The HT1080 fibrosarcoma-derived line was a 
gift from Ian Kerr, ICRF, London. SV40-transformed telomerase-positive human fibroblasts 
GM639 were obtained from the Coriell Institute for Medical Research, Camden, NJ. SV40-
transformed telomerase-negative human fibroblasts GM847 were obtained from Roger 
Reddel, Children’s Medical Research Institute, Sydney. HeLa cells were obtained from 
Beatrice Bentele, ISREC. SW480, a colon adenocarcinoma cell line, was obtained from 
Richard Iggo, ISREC. The above cells were maintained in high glucose DMEM with 10% 
fetal calf serum (FCS). The breast carcinoma cell line 21NT and its derivatives 21NT 
pCineohTERT (parental) and 21NT pCineohTERT HyTkchromosome 3 (21NT-chromosome 
3 hybrids) were cultured as described (Cuthbert et al., 1999). EREB 2-5 were obtained from 
Georg W. Bornkamm, GSF, Munich, and were cultured as described (Kempkes et al., 1995). 
HaCaT human adult skin keratinocytes (Boukamp et al., 1988) were obtained from Stephanie 
Lation, ISREC, and were maintained undifferentiated, in medium A (1:3 DMEM to HAM-
F12) containing 0.6 mM CaCl2, 5 % FCS, 8.3 ng/ml cholera toxin, 5 µg/ml insulin, 24 µg/ml 
adenine, 0.5 µg/ml hydrocortisone and 10 ng/ml EGF. After growth to confluence, the cells 
were induced to differentiate in medium A containing 1.2 mM CaCl2, 20 % FCS, 8.3 ng/ml 
cholera toxin, 5 µg/ml insulin, 24 µg/ml adenine and 0.5 µg/ml hydrocortisone for 14 days. 
For measuring RNA stability, HT1080 cells were treated with 2 µg/ml of Actinomycin D for 
0.5 to 8 h. HLF-hTERT cells were generated by infection of HLF cells with pMSCV-
puromycin-hTERT (Migliaccio et al., 2000). HLF-c-Myc cells were similarly generated using 
pBabe-puromycin-c-Myc obtained from Bruno Amati (Alevizopoulos et al., 1997). Infections 
were performed as described previously (Migliaccio et al., 2000). 
4.3.2 Plasmids 
pGRN121 contains hTERT cDNA (Nakamura et al., 1997) and was obtained from 
Geron Corporation, Menlo Park, CA. pNSV4 contains a genomic hTERT insert (Accession 
number AF114847) encompassing 7.4 kb of the 5’flanking region upstream of the hTERT 
translation start site, the first two exons and part of the second intron (Wu et al., 1999). pSV2-
Thy-1 expresses the mouse Thy-1.1 allele under the control of the SV40 enhancer and early 
promoter (Wilson et al., 1990). We constructed hTERT-GFP plasmids using the following 
procedures. To generate the GFP reporter vectors: pG (basic vector), pSVG (promoter vector) 
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and pSVEG (promoter/enhancer vector), we replaced the HindIII/XbaI fragment containing 
the luciferase gene of pGL3 (Promega) by the HindIII/XbaI fragment of pEGFP-N1 
(Clontech) containing the EGFP gene. phTERT.1.3G contains a 1.3 kb fragment upstream of 
the translation start site of the hTERT gene. The 1.3 kb fragment was amplified from pNSV4 
by PCR using oligonucleotides P1328f and P1r (see below) and subcloned into the NheI/BglII 
sites of the promoterless GFP vector. phTERT.5.1G, containing 5.1 kb of upstream sequence, 
was generated by cloning a 3.8 kb SacI/NheI fragment of pNSV4 into the SacI/NheI sites of 
phTERT.1.3G. phTERT.7.4G was generated by cloning a 2.3 kb SacI fragment of pNSV4 
into the SacI site of phTERT.5.1G. phTERT.4.8G was generated by religation of 
phTERT.7.4G after digestion with SpeI, deleting a 2.6 kb fragment from the 5’ end of the 
hTERT promoter. phTERT.3.3G was generated by subcloning a 3.3 kb XhoI/HindIII 
fragment of phTERT.5.1G into pG. phTERT.4.4G was obtained by cloning of a 1.1 kb 
SacI/XhoI fragment generated by PCR with primers P3061f and P4183r into the SacI/XhoI 
sites of phTERT.3.3G. We generated phTERT.0.9G, phTERT.0.6G and phTERT.0.3G like 
phTERT.1.3G except that oligonucleotides P951f, P602f and P314f, respectively, were used 
as forward primers. To generate phTERT.1.3∆0.1G and phTERT.1.3∆0.3G 108 bp and 160 
bp, respectively, of the 3' end of the 1.3 kb insert of phTERT.1.3G were removed by PCR 
using oligonucleotides P1328f, and P108r or P260r, respectively. 
4.3.3 DNA oligonucleotides 
The following DNA oligonucleotides were purchased from Microsynth (Balgach, 
Switzerland) and used for hTERT reporter constructs.  
P1r: 5'-GGAACTAGTAGATCTCGCGGGGGTGGCCGGGG-3’;  
P108r: 5'-GGAACTAGTAGATCTGGGAGGCCCGGAGGGG-3';  
P260r: 5'-GGAACTAGTAGATCTGTGCCCGCGAATCCACTG-3';  
P314f: 5'-GGAGGATCCGCTAGCAGCTGCGCTGTCGGGG-3';  
P602f: 5'-GGAGGATCCGCTAGCGCCTTCGTCCTCCCCTTC-3';  
P951f: 5'-GGAGGATCCGCTAGCGGGCGGGATGTGACCAG-3';  
P1328f: 5'-GGAGGATCCAGGGAGGGTGCGAGGCC-3'); 
P3061f: 5’-CATTTCCAGGAGCTCCCCGTCTC-3’;  
P4181r: 5’-TTGCAGGCCTGGGCTCGAGGC-3’ 
4.3.4 Transfections 
Transient transfections with calcium-phosphate precipitates were performed according 
to the protocol described by Jordan (Jordan et al., 1996). Cells were co-transfected with 1 µg 
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pSV2-Thy-1.1 as reference plasmid and equimolar amounts of GFP-reporters. The total 
amount of plasmid was kept constant (6 µg) by adding pUC19.  
 
4.3.5 Determination of reporter expression 
Transfected cells were harvested 48 h after transfection by trypsinization and incubated 
for 30 min with a saturating concentration of either monoclonal phycoerythryn (PE)-labeled 
anti-mouse CD90.1 (Thy-1.1) antibody OX-7 (Pharmingen, San Diego, CA) or 
allophycocyanin (APC) labeled anti-Thy-1 antibody III-5 (MacDonald et al., 1985) kindly 
prepared by Céline Maréchal, and washed once. We analyzed the cells on a FACS-scan or 
FACScalibur microflow cytometer (Becton Dickinson, Franklin Lakes, NJ). hTERT reporter 
gene expression was quantified by calculating the equivalent to the value used for enzyme 
reporter systems. For this we considered the arithmetic mean of GFP expression and Thy-1 
fluorescence. We subtracted from the arithmetic mean of GFP expression the GFP 
background, obtained with cells transfected only with pSV2-Thy-1. To correct for transfection 
efficiency, this value was divided by the equivalent measure for Thy-1 expression in the same 
cells. The GFP expression of the reporter constructs was normalized to that of a plasmid 
containing the SV40 minimal promoter driving GFP expression (pSVG). The GFP-reporter 
assay will be described in detail elsewhere (manuscript in preparation). 
4.3.6 Quantitative RT-PCR analysis 
Total RNA was extracted from different cell lines using the RNAeasy mini-kit 
(Qiagen). The quality of the RNA was determined on agarose gel electrophoresis. RNA was 
quantified with spectrophotometry at 260 and 280 nm (1OD260 ~40 µg/ml). To perform RT-
PCR with primer pairs that are not located in different exons or to quantify intron 2-
containing hTERT RNA, a DNase I treatment was performed prior to reverse transcription. 
Four µg total RNA was incubated in 20 µl with 10 U DNase I (Roche Diagnostics Ltd) in 10 
mM Tris-HCl pH 8.0, 0.5 mM MgCl2, 1 mM dithiotreitol, 0.2 U/µl RNasin (Roche 
Diagnostics Ltd) for 1 h at 37 °C, followed by 10 min at 65° C to inactivate the enzyme. We 
reverse-transcribed 100 ng of RNA in 20 µl using 100 ng of random hexamer primers and 
with 20 U of MMLV-RT (Gibco-BRL) according to the manufacturer’s protocol. To quantify 
intron 2 containing hTERT RNA, 1 µg of DNase I treated RNA was reverse transcribed as 
above using 10 pmol of primers 13156rv (E2-I2) and 10 pmol of primers 3407rv (GAPDH), 
respectively (Table 1). Quantitative PCR was performed using an ABI Prism 5700 Sequence 
Detection System (Perkin-Elmer Applied Biosystems, Foster City, CA). For each PCR run, a 
master mix was prepared with 1x TaqMan master mix or 1x SYBERGreen master mix (5.5 
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mM MgCl2, 200 µM dATP, 200 µM dCTP, 200 µM dGTP, 400 µM dUTP, 0.01 U/µl 
AmpErase UNG and 0.025 U/µl AmpliTaq Gold DNA Polymerase ± SYBR Green I dye) 
(Perkin-Elmer Applied Biosystem), 0.3 µM of each primer and 0.1 µM TaqMan probe. 2.5 µl 
of the reverse transcriptase reaction was added to 22.5 µl of master mix. The thermal cycling 
conditions included an initial denaturation step at 95°C for 10 min followed by 50 cycles at 
95°C for 15 sec and 60°C for 1 min. Primers and probes for all RT-PCR were chosen with the 
assistance of the computer program Primer express (Perkin-Elmer Applied Biosystems). 
BLASTN searches were used to check the gene specificity of the nucleotide sequences chosen 
for the primers and probes. PCR products were fractionated on agarose gel to confirm that 
their size corresponded to the expected length. Primers were purchased from Microsynth 
(Balgach, Switzerland), and TaqMan probes were from Eurogentec (Les Ulis Cedex, 
Belgium). To test the efficiency of the PCR primers, we carried out reactions with different 
concentrations of the appropriate template hTERT DNA (pGRN121, pNSV4) or GAPDH 
cDNA and plotted the cycle number at which the PCR signal raises above background (Ct) 
against the logarithm of the number of template molecules (L). The regression lines and 
correlation coefficients obtained were Ct=-3.29L+42.20, R2=0.997; Ct=-3.21L+39.59, 
R2=0.998; Ct=-3.62L+42.23, R2=0.997; Ct=-3.33L+35.40, R2=0.991 for hTERT E4-5, E9-10, 
E2-I2 and GAPDH primers, respectively. To test the efficiency of hTERT cDNA synthesis we 
used an in vitro transcript as template. Different quantities of this synthetic template were 
mixed with total RNA of telomerase negative HLF cells and reverse-transcribed. Comparison 
of Ct values obtained upon RT-PCR of the synthetic hTERT RNA with the Ct values obtained 
with known numbers of plasmid molecules showed that the efficiency of cDNA synthesis was 
25%. The amount of total RNAs obtained from different cells was measured by alkaline 
hydrolysis as described (Brandhorst and McConkey, 1974). Per million cells the following µg 
amounts of total RNA was present: HLF and HLF-c-Myc: 23 to 25 µg; GM847: 20 µg; 
HT1080: 35 µg; 21NT and 21NT-chromosome 3 hybrids: 21 to 23 µg; HeLa: 35 µg; SW480: 
20 µg; EREB: 30 µg. 
4.3.7 Preparation of nuclear and cytoplasmic extract 
Nuclear and cytoplasmic extracts were either prepared by hypotonic swelling according 
to Schreiber (Schreiber et al., 1989) or by dounce homogenization as described by Mirkovitch 
(Mirkovitch et al., 1992). The cytoplasmic fractions were then mixed (1:1) with the lysis 
buffer from the RNAeasy minikit (Qiagen) and the nuclear pellets resuspended in the same 
lysis buffer. 
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4.3.8 Cell cycle analysis 
Live HT1080 cells were stained with 10 µg/ml DAPI (Fluka) for 30 min at 4°C in PBS 
containing 0.05 % Triton X-100, and washed with PBS. Cells were sorted according to DNA 
content on a FACS-sorter microflow cytometer (BECTON DICKINSON, Franklin Lakes, NJ) 
and collected in lysis buffer from the RNAeasy mini-kit (Qiagen). 
4.3.9 Immunoblots 
Total protein from four independent cultures of subconfluent 21NT parental and 21NT-
chromosome 3 hybrids were extracted with 8M urea, 0.5% Triton X-100 and 0.5% NP40. 
Fifty µg of protein was resolved on a 10% SDS-polyacrylamide gel and transferred to 
nitrocellulose membranes. c-Myc protein was detected with a mouse monoclonal IgG against 
human c-Myc (9E10, 1/1000, Santa Cruz), Mad 1 with a rabbit polyclonal antibody (C-19, 
1/200; Santa Cruz) and actin with a goat polyclonal antibody (I-19, 1/200, Santa Cruz). 
Western blots were developed using the enhanced chemiluminescence system (ECL, 
Amersham) for actin and the SuperSignal West Pico kit (Pierce) for c-Myc and Mad1. 
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4.4 RESULTS 
4.4.1 hTERT RNA quantification and correlation with telomerase activity 
To measure the amount of hTERT RNA in tumor-derived cell lines and primary cells, 
we developed a quantitative RT-PCR assay using three different hTERT primer pairs (Table 
1). Two primer pairs, E4-5 and E9-10, spanned the boundary between exons 4 and 5, and 
between 9 and 10, respectively, and only amplified cDNA from spliced RNA lacking intron 4 
and/or 9, whereas the third primer pair, E2-I2 amplified cDNA from immature hTERT RNA 
containing the end of exon 2 and 256 nt of intron 2. For comparison, we determined the 
amount of intron free GAPDH RNA. The number of cDNA molecules present in a sample 
was calculated by plotting the corresponding Ct value onto the regression line of the Ct values 
obtained when graded amounts of precisely quantified hTERT plasmid or GAPDH PCR 
product were amplified. As the efficiency of cDNA synthesis from an in vitro transcript of 
hTERT in the presence of total RNA of telomerase negative cells was 25 % (data not shown), 
the number of intron free hTERT RNA molecules was assumed to correspond to the 
quadruple of the estimated number of cDNA molecules. We obtained the same estimates of 
hTERT RNA molecule numbers using either the E4-5 or the E9-10 primer pairs (data not 
shown). 
 Telomerase-positive tumor-derived cell lines contained between 0.2 and 6 spliced 
hTERT RNA molecules/cell (Fig. 1A). No signal above the detection limit of 0.004 
molecules/cell was obtained in telomerase-negative primary human lung fibroblasts or in the 
telomerase-negative cell line GM847 (Fig. 1A). Therefore, if telomerase-negative cells 
express any spliced hTERT RNA at all, its level is at least 50-1500 times lower than that of 
telomerase-positive cells. Primary fibroblasts that were transduced with an hTERT-retroviral 
construct expressed at least 100 times more spliced hTERT RNA than tumor-derived cells but 
their telomerase activity was not higher than tumor-derived cells (data not shown). Fibroblasts 
expressing c-Myc contained spliced hTERT RNA at levels comparable to those in some 
telomerase-positive tumor cells (0.2 molecule/cell) (Fig. 1A). Quantification of GAPDH RNA 
demonstrated that each cell contained between 700 and 15’000 molecules (Fig. 1A). Thus, by 
comparison to GAPDH, hTERT is a very rare RNA species, detectable exclusively in 
telomerase-positive cells.  
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TABLE 1 Synthetic oligonucleotides used as primers for RT-PCR.  
Name Primers 
and 
TQa probes 
Localization
exon/intron
(E/I) 
Sequences 
5'-3' 
Primer 
length 
(nt) 
Amplicon 
length 
(bp) 
E2-I2 12896fw E2 GAGCTGACGTGGAAGATGAGC 21 260 
 13156rv I2 GGTGAACCTCGTAAGTTTATGCAA 24  
  13095TQ I2 CACGGTGATCTCTGCCTCTGCTCTCC 26  
      
E9-10 2600fw E9 ATGGAGAACAAGCTGTTTGCG 21 80 
 2680rv E10 AGGTGTCACCAACAAGAAATCATC 24  
 2635TQ E9/E10 CGGGCTGCTCCTGCGTTTGG 20  
      
E4-5 1949fw E4 TGCGGCCGATTGTGAAC 17 98 
 2046rv E5 GAACAGTGCCTTCACCCTCG 20  
      
hTER F3b 45  TCTAACCCTAACTGAGAAGGGCGTAG 26 125 
 R3c 170 GTTTGCTCTAGAATGAACGGTGGAAG 26  
      
GAPDH 1457fw E1 GAAGGTGAAGGTCGGAGT 18 226 
 3407rv E3 GAAGATGGTGATGGGATTTC 20  
      
β2-M c 531fw 531 b TCTACTTTGAGTGCTGTCTCCATGT 25 76 
 606rv 606 b TTGCCAGCCCTCCTAGAGC 19  
      
c-MYC 5189fw E2 GCTCTCCTCGACGGAGTCC 19 134 
 6689rv E3 CCACAGAAACAACATCGATTTCTT 24  
      
MAD 356fw 356 b TCGACCAGCTTCAGCGAGA 19 91 
 446rv 446 b GTGGAGCCGATGCTGTCC 18  
      
CAD 329fw 329 b CAGGTTTGCCAGCTGAGGA 19 116 
 444rv 425 b TGCCTGTCTCGGTACTGGTG 20  
      
ODC ODCfw 591 b TGTAGGAAGCGGCTGTAC 18 228 
 ODCrv 798 b GCTATGATTCTCACTCCAGAG 21  
      
GADD45 149fw 149 b ACCCCGATAACGTGGTGTTG 20 91 
 239rv 239 b GCCTGGATCAGGGTGAAGTG 20  
      
EIF4E 388fw 388 b TGGCTAGAGACACTTCTGTGC 22 91 
 468rv 468 b AACATTAACAACAGCGCCACAT 22  
      
LDHA 196 196 b CAACATGGCAGCCTTTTCCT 20 91 
 286 286 b CCGTGATAATGACCAGCTTGG 21  
      
U3 U3f 178 b ACCACGAGGAAGAGAAGTAGCG 22 64 
 U3r 225 b GCCAAGCAACGCCAGAA 17  
a) TQ = TaqMan probe 
b) Position in the mature RNA 
c) β2-microglobuline 
 
4.4.2 Regulation of hTERT RNA levels in the nucleus 
While it is generally assumed that hTERT expression is regulated primarily at the level 
of transcription there is little direct evidence for this. In support of this notion overexpression 
of c-Myc can directly induce hTERT expression (Greenberg et al., 1999; Wu et al., 1999). 
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Furthermore, hTERT run-on transcription signals (Gunes et al., 2000) changed during 
differentiation of human hematopoietic U937 cells. We have been unable to detect run-on 
transcription signals from the hTERT gene with cells used in this study (A-L. D. and J. 
Mirkovitch, unpublished data) which contain only 0.2 - 6 spliced hTERT RNA 
molecules/cell. To substantiate the assumption that hTERT expression is regulated in the 
nucleus, we compared the amounts of various spliced and unspliced hTERT RNAs in the 
nucleus and the cytoplasm. Nuclear and cytoplasmic fractions of HT1080 cells were prepared 
according to two different protocols (Mirkovitch et al., 1992; Schreiber et al., 1989). Both 
methods produced very similar results for hTERT RNAs as well as for control RNAs 
(GAPDH and U3 snRNA; Fig. 1B). The two controls were included to monitor contamination 
between nuclear and cytoplasmic fractions. Such contamination was low as only 4 % of 
GAPDH RNA was found in the nuclear fraction, while 93 to 98 % of the U3 snRNA appeared 
in the nuclear fraction (Fig. 1B). However, 20 - 30 % of the telomerase RNA compound 
hTER, which was previously thought to be mostly nuclear, was also detected in the 
cytoplasm. On the other hand, we found a considerable fraction (35 - 75 %) of hTERT RNAs 
in the nucleus. This included transcripts still retaining intron 2 as well as molecules lacking 
intron 4 and/or intron 9. However, hTERT negative cells lacked both intron-containing and 
intron-less hTERT RNA (Fig. 1A).  
We also analyzed the stability of spliced and unspliced hTERT RNA in HT1080 cells 
treated with Actinomycin D. Half-lives of intron 9-less and intron 2-retaining hTERT RNAs 
were 2 h and 2.5 h, respectively (data not shown). A slightly shorter half-life of 50 min for 
hTERT mRNA was found in human hematopoietic U937 cells (Gunes et al., 2000). Since no 
form of hTERT RNA was detected in telomerase-negative cells, we conclude that hTERT 
regulation occurs in the nucleus. 
hTERT RNA levels do not change during the cell cycle but decrease upon cell cycle 
exit and terminal differentiation. To determine whether RNA levels of hTERT fluctuate 
during the cell cycle, exponentially growing HT1080 cells were stained with DAPI and sorted 
by fluorescence flow cytometry (FACS) according to their DNA content (Fig. 2A). The 
fluorescence-activated cell sorter sorting gates were set sufficiently narrow to minimize cross-
contamination of cells from different phases of the cell cycle. Total RNA was extracted and 
hTERT RNA levels were measured by quantitative RT-PCR. We found no significant 
differences between spliced hTERT RNA levels in the different phases of the cell cycle (Fig. 
2B). 
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Figure 1: hTERT RNA quantification and subcellular localization. (A) Quantification of intron 9-less 
(black bars) and intron 2-retaining (white bars) hTERT RNA and GAPDH RNA (right panel). RNA was 
extracted from cells, reverse transcribed and analyzed by quantitative PCR with hTERT primer pairs E9-10 and 
E2-I2 and primers for intron-less GAPDH mRNA. Results represent the average (± range) of 1 to 6 different 
RNA extractions and RT-PCR experiments. HLF, primary human lung fibroblasts; HLF-hTERT, HLF 
transduced with MSCV-hTERT retrovirus; HLF-c-Myc, HLF transduced with pBabe-c-Myc; 21NT chro3, 21NT 
chromosome 3-hybrids. undiff HaCaT, undifferentiated HaCaT; diff HaCaT, differentiated HaCaT; EREB + E2, 
proliferating EREB; EREB – E2, starved EREB; ND, not determined. 
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Figure 1: hTERT RNA quantification and subcellular localization. (B) Subcellular distribution of intron 
4-less, intron 9-less and intron 2-containing hTERT RNA. Nuclear and cytoplasmic fractions of HT1080 were 
prepared according to two different methods, and treated with DNase I prior to the RT reaction. Bars represent 
the average of percentage of RNA in the nuclear fraction, obtained from 2 to 4 independent experiments. U3 
served as a control for the contamination of cytoplasmic fraction with nuclear RNA. GAPDH served as a control 
for the contamination of nuclear with cytoplasmic RNA.  
 
Using EREB cells, we investigated whether the proliferative state of the cells affected 
hTERT RNA levels. EREB cells are EBNA2-immortalized B-lymphocytes in which the 
EBNA2 gene is expressed as a chimeric fusion with the hormone-binding domain of the 
estrogen receptor. Thus, proliferation of the cells depends on the presence of estrogen 
(Kempkes et al., 1995). As expected, the number of cells in G1 increased when EREB cells 
were cultured for 24 h in the absence of estrogen (from 60 to 90%; not shown). Estrogen 
deprival lead also to a five-fold reduction of spliced and intron-containing hTERT RNAs (Fig. 
1A). A very strong decrease in hTERT RNA levels was seen upon terminal differentiation of 
immortalized human skin keratinocytes (HaCaT). HaCaT cells remain undifferentiated when 
cultured in low calcium. The addition of calcium to confluent cells is sufficient to induce cell 
differentiation. After six days into high calcium medium, spliced and unspliced hTERT RNA 
levels had dropped at least 300-fold compared to undifferentiated HaCaT cells (Fig. 1A). 
These results demonstrate that while hTERT RNA levels do not vary during different stages 
of the cell cycle in tumor-derived cells, the levels of hTERT RNA are significantly reduced 
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by cell cycle arrest and/or terminal differentiation. Diminution of spliced hTERT RNA during 
cell differentiation has been previously reported for U937 and HL-60 hematopoietic cells 
(Gunes et al., 2000; Meyerson et al., 1997). 
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Figure 2: hTERT RNA levels during the cell cycle. (A) Subconfluent HT1080 cells were stained with 
DAPI and sorted by flow cytometry (FACS) according to their DNA content. The sorted cells were directly 
lysed and total RNA was prepared. The grey boxes represent the gates used to sort G1, S and G2/M phase cells, 
respectively. (B) Intron 9-less hTERT RNA level was quantified for each cell cycle phase. It was normalized to 
intron-less GAPDH and expressed relative to the amount in G1 phase cell. Results represent the average (± 
range) of 2 independent experiments.  
 
4.4.3 Characterization of the 5’ region of the hTERT gene 
The results above are consistent with the hypothesis that hTERT RNA levels are 
regulated by transcription. To examine the regulatory role of the hTERT 5’ flanking region, 
DNA fragments upstream of the start codon were fused to the GFP gene (Fig. 3A). Expression 
of these reporter constructs was quantified by two-color fluorescence flow cytometry (FACS) 
(see Materials and methods). As shown in figure 3B, reporters containing up to 7.4 kb of 
hTERT 5’ flanking region expressed GFP in HT1080 cells. In telomerase-negative HLF cells, 
the reporters containing either the 1.3 kb or the 3.3 kb of 5’flanking region expressed low 
GFP fluorescence, while the other constructs did not express GFP at levels that were 
significantly above that of the background observed with a promoter-less construct (pG) (data 
not shown). Removal of 260 nt immediately upstream of the start codon (phTERT.1.3∆0.3G) 
completely abolished the weak GFP expression in HLF cells, and strongly reduced it in 
HT1080 cells. Similar results were obtained using telomerase-positive HeLa cells (data not 
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shown). Thus, as expected, the hTERT-GFP reporters activated GFP expression in tumor-
derived cell lines but not in telomerase-negative primary human lung fibroblasts.  
The reporters also induced GFP expression to similar levels in two SV40-transformed 
fibroblast lines (Fig. 3C). Of these, GM639 is telomerase-positive and contains detectable 
hTERT RNA (Fig. 1A). GM847, on the other hand, is telomerase-negative and contains 
neither intron 2-containing or intron 9-less hTERT RNA (Fig. 1A). Thus, the hTERT-GFP 
reporter activity in these fibroblast lines did not mimic hTERT RNA expression. 
We investigated whether the hTERT-GFP reporter constructs could be used to identify 
regulatory elements in a breast carcinoma cell line, 21NT. Introduction of a normal human 
chromosome 3 in these cells, by microcell fusion, represses telomerase activity (Cuthbert et 
al., 1999). This indicates that cis-acting targets of repression in the 21NT hTERT genes are 
intact. Repression of telomerase activity by chromosome 3 transfer is mediated by down-
regulation of the hTERT RNA (Fig. 1A). We tested whether the hTERT-GFP reporter 
constructs would also be repressed by chromosome 3. To avoid cell senescence as a result of 
hTERT extinction (Cuthbert et al., 1999), hTERT was ectopically expressed in the parental 
and in the hybrids cells. Fig. 3D shows representative results for 4 independent hybrids out of 
the 10 tested. As expected, we detected no intron 2-containing hTERT RNA in the 21NT-
chromosome 3 hybrids. In contrast, GFP expression in the hybrids was the same as in the 
parental cells. We obtained similar results after stable transfection of the reporter constructs 
(data not shown). Therefore, it appears that the regulatory elements required for repression of 
hTERT in GM847 cells and 21NT-chromosome 3 hybrids are not contained within the 7.4 kb 
region upstream of the hTERT start codon or that they do not function properly when 
removed from their endogenous location. 
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Figure 3: hTERT-GFP reporter assay. (A) Features of the 7.4 kb 5’ flanking region, the first two exons, 
and part of the second intron of the hTERT gene. Putative transcription factor binding sites in the promoter 
region of the hTERT gene are indicated. (B) Schematic representation of the hTERT-GFP reporter plasmids that 
were transfected into normal human fibroblasts (HLF) (black bars) and HT1080 fibrosarcoma cells (grey bars). 
Cells were co-transfected with the indicated plasmids plus pSV2Thy-1.1, harvested 48 h later, stained with an 
excess of allophycocyanin-coupled anti-Thy-1 antibody and analyzed by microflow cytometry. To correct for 
transfection efficiency, mean GFP fluorescence was corrected by the mean fluorescence for Thy-1. Results are 
expressed relative to the GFP expression of the control plasmid containing the SV40 promoter upstream of GFP 
(pSVG) and are average values (± standard deviations) of the number of independent transfection experiments 
shown in the figure. (C) hTERT-GFP reporter expressions in two SV40T-immortalized fibroblast cell lines: 
telomerase-positive GM639 (black bars) and telomerase-negative GM847 (grey bars). The experiment was 
performed as in B. (D) Expression of different hTERT-GFP reporters in parental breast cancer cells (21NT) and 
in four telomerase-negative 21NT chromosome 3-hybrids containing an extra normal human chromosome 3. The 
experiment was performed as in B. Numbers at the right indicate relative levels of endogenous hTERT 
transcripts. RT-PCR was performed with primer pairs E2-I2.  
 
4.4.4 Chromosome 3-mediated hTERT down-regulation does not involve the c-Myc 
regulatory network 
Previous studies showed that overexpression of c-Myc can induce hTERT expression in 
telomerase-negative cells (Greenberg et al., 1999; Wang et al., 1998; Wu et al., 1999). 
Therefore, we tested whether hTERT RNA down-regulation in 21NT-chromosome 3 hybrids 
was associated with changes in the c-Myc pathway. Similar levels of c-Myc and Mad1 
proteins were detected in parental and hybrid cells (Fig. 4A). Furthermore, using quantitative 
RT-PCR, we found that parental and hybrid cells expressed the same c-Myc and Mad RNA 
levels indicating that c-Myc is not a target of the putative repressor on chromosome 3 (Fig. 
4B). To determine whether the chromosome 3-repressor would act on other genes or gene-
products of the c-Myc regulatory network we measured the expression levels of five known c-
Myc target genes: CAD, ODC, GADD45, eIF4E and LDHA (Dang, 1999). The RNA levels 
of CAD, ODC, GADD45, eIF4E and LDHA in the 21NT parental cells and chromosome 3 
containing hybrids were very similar whereas hTERT RNA levels dropped at least 30 fold 
(Fig. 4B). We conclude that the repressor on chromosome 3 defines a regulatory pathway 
controlling hTERT expression that does not involve c-Myc. 
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Figure 4: c-Myc levels in parental 21NT cells and 21NT-chromosome 3 hybrids. (A) c-Myc, Mad1 and 
actin protein levels in 21NT parental cells and 21NT-chromosome 3 hybrids. Total protein was extracted from 
two cultures of exponentially growing parental 21NT and two cultures of 21NT-chromosome 3 hybrid cells. c-
Myc, Mad1 and actin levels were determined by Western analysis. (B) Relative levels of hTERT, c-Myc, Mad, 
CAD, ODC, GADD45, eIF4E and LDH RNAs in 21NT parental cells and 21NT-chromosome 3 hybrids. Total 
RNA was extracted from exponentially growing parental 21NT cells (white boxes) and of 21NT-chromosome 3 
hybrids (grey boxes). To avoid genomic contamination, RNA was treated with DNAse I prior to reverse 
transcription. Real-time RT-PCR was performed with primer pairs hTERT E2-I2, MYC, MAD, CAD, ODC, 
GADD45, eIF4E, LDHA and β2M. RNA levels were normalized to β2M RNA and are expressed relative to the 
RNA level in parental 21NT cells. Results represent the average (± range) of two independent experiments with 
two parental 21NT cells and two independent 21NT-chromosome 3 hybrids. 
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4.5 DISCUSSION 
 In this paper, the transcripts of the gene coding for the catalytic subunit of human 
telomerase were quantified in different telomerase-positive and negative cells. Intron 9-less 
and intron 2-containing transcripts of hTERT were detected in telomerase-positive cell lines 
but not in telomerase-negative HLF and GM847 cells. These results provide support for the 
critical role of hTERT RNA regulation for telomerase activity. Our data indicate that on 
average, a telomerase-positive cell contains less than six spliced hTERT RNA molecules, 
whereas spliced and intron-containing hTERT RNA levels in telomerase-negative cells, if 
present, are below the limit of detection (0.004 molecule/cell). We found that intron 9-less 
and intron 4-less hTERT RNAs were predominantly cytoplasmic, whereas intron 2-containing 
hTERT RNA was mainly nuclear. The relative levels of both RNA species correlated well 
with each other in all telomerase-positive and negative cells examined. These data suggest 
that hTERT RNA levels are controlled mainly prior to exit from the nucleus, by changes 
either in the rate of transcription or in the stability of nuclear RNA.  
The low hTERT RNA levels combined with the intermediate RNA stability suggest that 
the rate of hTERT transcription is low. Assuming a polymerization rate of 2000 
nucleotides/min by RNA polymerase II (Jackson et al., 2000) and a half-life for hTERT RNA 
of 2 h we estimate that 1-2 RNA polymerase complexes are transcribing the 40 kb gene (Wick 
et al., 1999) at any given time. This low RNA polymerase II density on the hTERT gene is 
consistent with our inability to detect hTERT transcription by run-on analysis (not shown). 
However, successful run-on analysis was reported by Günes (Gunes et al., 2000) using human 
myeloid leukemia U937 cells. Comparison of their data with ours suggests that the rate of 
hTERT transcription in U937 cells is much higher than in HT1080 fibrosarcoma cells.  
In previous reports several hTERT RNA splice variants had been described which are 
differentially expressed during embryonic development and could also be detected in some 
immortal cell lines (Kilian et al., 1997; Ulaner et al., 1998; Wick et al., 1999). The splice-
variants cannot encode enzymatically active telomerase since critical regions in the RT-
domain are missing. Since in the telomerase-negative cells tested here (HLF, GM847 and 
21NT-chromosome 3 hybrids) no hTERT transcripts were detectable, telomerase-repression is 
likely to involve mechanism(s) preceding alternative splicing.  
In arrested EREB cells and in terminally differentiated HaCaT cells we observed down-
regulation of hTERT RNA, whereas no change was detected during the cell cycle in 
proliferating tumor cells. This is reminiscent of the RNA levels of other DNA polymerases 
(α, δ and ε) in proliferating cells (Huang et al., 1999; Tuusa et al., 1995). It is unclear what 
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factors increase hTERT RNA levels in proliferating cells and whether the same factors 
mediate hTERT up-regulation in tumors. c-Myc is known to trigger hTERT transcription 
when over-expressed, and is expressed in proliferating but not in arrested cells. Thus, c-Myc 
may contribute to the activation of hTERT transcription in proliferating EREB and HaCaT 
cells. However, the levels of c-Myc present in proliferating fibroblasts are not sufficient to 
induce hTERT expression. The c-Myc protein is expressed at higher levels in many tumors, 
and may contribute to the activation of hTERT expression. However, transfer of normal 
chromosome 3 into the breast cancer-derived cell line 21NT repressed hTERT expression 
without affecting c-Myc or Mad levels or expression of c-Myc target genes. This indicates 
that the gene(s) on chromosome 3 responsible for hTERT repression does (do) not act via 
changes in the Myc/Mad network. Genetic or epigenetic events other than changes in c-Myc 
levels must be required for hTERT activation in the tumor that gave rise to 21NT cells. 
Our results strongly suggest that chromosome 3 acts to repress telomerase through 
transcriptional silencing of the gene encoding hTERT. In our previous study (Cuthbert et al., 
1999) we were unable to obtain definitive proof that replicative senescence induced by 
chromosome 3 was exclusively due to telomerase repression. In the present study we used, as 
recipients, 21NT cells that had previously been transfected with an hTERT cDNA expression 
construct in an attempt to prevent senescence resulting from repression of endogenous 
telomerase activity. The fact that chromosome 3 transfer did not induce senescence in these 
hTERT cDNA-transfected recipients, while endogenous hTERT immature RNA was down-
regulated, clearly establishes that the effect of the repressor on chromosome 3 in inducing 
senescence is due entirely to a specific silencing effect on hTERT expression. 
Like others we have developed hTERT constructs in which 5’ flanking segments of the 
hTERT gene drive expression of a reporter gene. Our data are in agreement with previous 
studies (Cong and Bacchetti, 2000; Cong et al., 1999; Fujimoto et al., 2000; Greenberg et al., 
1999; Gunes et al., 2000; Kyo et al., 1999; Kyo et al., 2000; Oh et al., 1999; Oh et al., 1999; 
Oh et al., 2000; Takakura et al., 1999; Wick et al., 1999; Wu et al., 1999) in that the hTERT 
promoter is active in telomerase-positive immortal cell lines, but barely so in telomerase-
negative primary cells. However, we also describe examples in which hTERT reporter 
expression does not mimic expression of the endogenous gene. Firstly, the reporters are as 
active in the telomerase-negative ALT cell line GM847 as in another telomerase-positive 
SV40-transformed fibroblast line, GM639. Secondly, in microcell hybrids in which 
chromosome 3 turns off expression of endogenous hTERT, the activity of the reporter 
constructs is not affected. In contrast, Horikawa (Horikawa et al., 1999) found that in RCC23-
chromosome 3 hybrids, luciferase expression was abrogated using a reporter containing 1.7 
kb of hTERT upstream region. The discrepancy between the reporter analysis in RCC23-
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chromosome 3 hybrids and in 21NT-chromosome 3 hybrids remains to be addressed. 
Endogenous hTERT RNA levels are influenced by the proliferative state of the cells (see Fig 
1A EREB and HaCaT cells) (Gunes et al., 2000; Pendino et al., 2001; Tzukerman et al., 2000, 
Xu et al., 2001). Different growth rates were observed for RCC23 cells and for RCC23-
chromosome 3 hybrids (Horikawa et al., 1998), whereas 21NT and 21NT-chromosome 3 
hybrids containing an hTERT transgene proliferated at the same rate (data not shown). 
Analyses of GFP reporters in 21NT-chromosome 3 hybrids and GM847 cells show that the 
region extending 7.4 kb upstream of the hTERT promoter is not sufficient to confer proper 
regulation outside its endogenous context.  
The hTERT gene resides very close to the telomere of the short arm of chromosome 5 
(Bryce et al., 2000). Telomeric chromatin in yeast is transcriptionally silent (Gottschling et 
al., 1990) and recent evidence indicates that telomeric repression exists also in human cells 
(Baur et al., 2001). Thus, it is tempting to speculate that the chromatin structure near the 
telomere may play an important role in the repression of the hTERT gene in normal human 
somatic cells, and that the repressor gene on chromosome-3 may in part exert its effect 
through chromatin remodeling. 
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5 REGULATION OF HUMAN TERT BY NOTCH SIGNALING 
 
5.1 ABSTRACT 
Telomerase is a reverse transcriptase that maintains the ends of chromosomes. Its 
activity is limited by the expression of its catalytic subunit, hTERT. In human, hTERT RNA 
is detected in tumors, but not in most somatic cell types. During embryonic development 
hTERT expression is reduced in fetal tissues after 16 to 20 weeks of gestation. The Notch 
signaling pathway controls cell fate decisions during embryonic development and Notch 
expression is up-regulated in some cancers. Therefore we considered the possibility that 
Notch controls hTERT expression during development and tumors. Overexpression of the 
intracellular part of Notch1IC, which is the active form of Notch1, up-regulated hTERT RNA 
in a breast cancer-derived cell line (21NT), whereas it reduced hTERT RNA levels in HeLa 
and HLF-cMyc cells. We identified several putative binding sites for CBF1, a known 
downstream effector of Notch1IC, in the hTERT gene. Two of these binding sites overlap 
with E-boxes that had previously been implicated in hTERT regulation. However we have no 
evidence for a direct interaction between Notch1IC and the hTERT gene. Using conditional 
Notch1IC knockout mice we found that depletion of Noch1IC did not affect liver TERT RNA 
levels, suggesting that Notch1IC may not be involved in the regulation of the mouse TERT 
gene, which also lacks the putative binding sites for CBF1.  
 
5.2 INTRODUCTION 
Telomerase is a ribonucleoprotein complex required for the addition of telomeric 
repeats to the ends of linear chromosomes. The core of the telomerase consists of the catalytic 
subunit, a reverse transcriptase, hTERT, and an RNA moiety that contains the template region 
for telomere elongation (hTERC). hTERT mRNA expression is limiting for telomerase 
activity in telomerase negative cells (Bodnar et al., 1998; Morales et al., 1999; Vaziri and 
Benchimol, 1998; Yang et al., 1999). In man telomerase is found in 85 % of tumor-derived 
cells (Kim et al., 1994), whereas no telomerase activity is detectable in the majority of 
somatic cells. hTERT expression is developmentally regulated. Enzyme expression is 
restricted to germ-line tissues, blastocysts and fetal tissues up to 16 to 20 weeks of gestation 
(Ulaner and Giudice, 1997; Wright et al., 1996). Proteins, which control cell differentiation 
and which are frequently up-regulated in cancer may be involved in hTERT regulation and 
Notch is such a potential regulator of hTERT expression. Indeed the Notch pathway controls 
cell fate decisions during development in organisms from Drosophila to humans (Artavanis-
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Tsakonas et al., 1999, Artavanis-Tsakonas, 1995 #419). Notch signaling influences distinct 
cellular processes such as differentiation, proliferation and apoptosis (Artavanis-Tsakonas et 
al., 1999; Miele and Osborne, 1999; Milner and Bigas, 1999). In particular, Notch activation 
inhibits or delays cell differentiation in developmental pathways (Delfini et al., 2000; Lam et 
al., 2000; Milner et al., 1996; Nofziger et al., 1999; Shawber et al., 1996). Thus, we 
speculated that Notch might prevent hTERT down-regulation in undifferentiated cells and in 
tumors. 
Notch genes encode transmembrane receptors (Fig. 1). Four vertebrate notch genes 
denominated notch1-4 have been identified. They are strongly related to each other and to 
Drosophila notch (Lardelli et al., 1995; Sugaya et al., 1997). Notch signaling is believed to 
mediate communication between neighboring cells, since Notch activation results from the 
binding of ligands expressed on adjacent cells. Ligand binding induces proteolytic processing 
of Notch that releases the intracellular portion of the receptor (NotchIC) from the plasma 
membrane. It is thought that NotchIC translocates to the nucleus where it interacts with 
effector molecules to alter gene expression (Jarriault et al., 1995; Kopan et al., 1996). One 
such effector molecule is the transcriptional regulator CBF1 (Grossman et al., 1994), also 
called RBP-JK or RBP-2N (Dou et al., 1994; Hamaguchi et al., 1989). CBF1 is homologous 
to Drosphila Su(H) (Furukawa et al., 1992) and to C. elegans Lag-1 (Christensen et al., 
1996). CBF1 directly interacts with Notch1IC (Hsieh et al., 1996; Jarriault et al., 1995) and 
recognizes the core DNA sequence GTGGGAA (Tun et al., 1994). DNA-bound CBF1 may 
act as transcriptional repressor by recruiting a co-repressor complex. Components of the co-
repressor complex identified by 2-hybrid screens, GST-pull down and transcriptional reporter 
assays include CIR, SMRT, SKIP, NCoR, SAP30, Sin3A, HDAC1 and HDAC2 and KyoT2 
(Hsieh et al., 1999; Kao et al., 1998; Taniguchi et al., 1998). Through interaction with 
NotchIC CBF1 is converted from a repressor of transcription into a transcriptional activator 
(Fortini and Artavanis-Tsakonas, 1994; Hsieh et al., 1996; Jarriault et al., 1995; Oswald et al., 
1998; Stifani et al., 1992; Tamura et al., 1995). To displace the co-repressor complex from 
CBF1, NotchIC may recruit co-activators such as Mastermind, p300, GCN4 and PCAF 
histone acetylases (Kurooka and Honjo, 2000; Oswald et al., 2001; Wu et al., 2000). The 
same region of CBF1 appears to interact with the co-repressors and the activators (Hsieh and 
Hayward, 1995; Hsieh et al., 1996; Tani et al., 2001), supporting a model of competition 
between co-repressors and co-activators for binding to CBF1.  
To explore whether rodent and human TERT expression might be modulated by Notch 
signaling, we compared both 5’ flanking region and searched for CBF1 binding sites in the 
TERT genes. We over-expressed Notch1IC in the breast cancer cell line 21NT, in the cervical 
carcinoma cell line HeLa, and in telomerase negative cells. We chose these cell lines because 
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the intracellular part of Notch 1 or Notch 4 are able to transform mouse mammary epithelial 
cells (Dievart et al., 1999; Gallahan and Callahan, 1997; Gallahan et al., 1987; Jhappan et al., 
1992) and because Notch1 and 2 are overexpressed in 100% of the cervical cancers analysed 
(Daniel et al., 1997; Zagouras et al., 1995). Using conditional Notch1IC knockout mice we 
investigated whether depletion of Noch1IC affects liver mTERT RNA levels. 
 
 
Figure 1: A) Notch receptors. The Notch receptor is a heterodimer of an extracellular domain (EGF, 
L/N), which is linked through a transmembrane domain (TM) to an intracellular domain (IC). The RAM domain 
adjacent to the transmembrane domain is the major docking site for the CBF1 protein (Aster et al., 1997; 
Jarriault et al., 1995; Tamura et al., 1995). The ankyrin repeats (ANK) adjacent to the RAM domain mediate 
protein-protein interactions (Artavanis-Tsakonas et al., 1999). The C-terminal region contains a polyglutamine 
region (OPA) and a proline, glutamic acid, serine and threonine rich region termed PEST. B) The two Notch1IC 
constructs used in this study are presented. Both constructs lack the extracellular and the transmembrane 
domains. In Notch1IC (R) the OPA and PEST motifs are deleted. In the Notch1IC (D) only the PEST sequence 
is missing. 
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5.3 MATERIALS AND METHODS 
5.3.1 Cells 
Primary human embryonic lung fibroblasts (HLF, a generous gift of Urs Ziegler, 
University Hospital, Zürich), c-Myc-immortalised HLF cells (HLF-c-Myc (Ducrest et al., 
2001), a cervical carcinoma derived-cell line (HeLa, obtained from Beatrice Bentele, ISREC) 
and Phoenix cells, packaging cells derived from the 293 cell line (a gift from a Garry Nolan, 
Stanford University, CA) were maintained in high glucose DMEM with 10% fetal calf serum. 
The breast carcinoma cell line 21NT and its derivative 21NT pCineohTERT 
HyTkchromosome 3 (21NT-chromosome 3 hybrid) were cultured as described (Cuthbert et 
al., 1999).  
5.3.2 Plasmids 
The murine Notch1IC-R cDNA (nucleotide position 1751-2294 of the ORF) was 
isolated from pSKN1IC (obtained from F. Radtke) by digestion with HindIII and EcoRI. 
Upon ligation of EcoRI linkers (New England Biolabs) it was subcloned into the pBabe 
retrovirus. The pBabeNotch1IC-D construct (nucleotides position 1751-2444 of the ORF) was 
obtained from Kenneth Raj (ISREC). The GFP reporter vectors pd2G (basic vector), pSVd2G 
(promoter vector) and pSVEd2G (promoter/enhancer vector) were generated as described in 
chapter 3. The putative CBF1 binding sites were mutated from GTGGGAA to GTGGCCA 
for site (A) that lies 23 bp upstream of the translation start site, from CTCCCAC to 
CTGGCAC for site (B) at position -240 bp and from TTCCCAC to TGGCCAC for site (C) 
at position –820 bp. These mutations abolished CBF1 binding activity in gel shift assays (Tun 
et al., 1994).The CBF1 binding site mutants were prepared from the phTERT.1.3G reporter 
construct (Ducrest et al., 2001) by PCR with the primers described below. The 
phTERT.1.3d2G variants were obtained by cutting phTERT.1.3G with NheI and BglII and 
ligating the respective fragments into pd2G also cut with NheI and BglII. The mutation A was 
obtained by cloning a 1.3 kb NheI/BglII fragment generated by PCR with primers P1328f and 
CBF-A2r and with phTERT.1.3G as template into the NheI/BglII sites of pd2G. The mutation 
B was obtained in two steps. First a fragment of 0.25 kb was generated by PCR with primers 
CBF-B2fw and P1r and with phTERT.1.3G as template. Then this product was used as primer 
with P1328f in a second PCR with phTERT.1.3G as template. The final 1.3 kb product was 
cloned as described above. The mutation C was obtained in two steps. First a fragment of 0.5 
kb was generated by PCR with primers CBF-Cr and P1328f and with phTERT.1.3G as 
template. Then this product was used as primer with P1r in a second PCR with phTERT.1.3G 
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as template. The final 1.3 kb product was cloned as described above. The combined mutation 
AB was obtained by generating by PCR amplification of a fragment of 0.2 kb with primers 
CBF-B2f and CBF-A2r and with phTERT.1.3G as template. This product was used as primer 
with P1328f and with phTERT.1.3G as template in a second PCR producing the final 1.3 kb 
fragment that was cloned as described above. The mutation AC was obtained by generating 
by PCR amplification of a fragment of 0.5 kb with primers P1328f and CBF-Cr and with 
phTERT.1.3G as template. This product was used as primer with CBF-A2r and with 
phTERT.1.3G as template in a second PCR producing the final 1.3 kb fragment that was 
cloned as described above. The mutation BC was obtained by generating by PCR 
amplification of a fragment of 0.5 kb with primers p1328f and CBF-Cr and with 
phTERT.1.3G as template. In a second PCR a 0.25 kb fragments was generated with primers 
CBF-B2f and P1r and with phTERT.1.3G as template. These two products were used as 
primers with phTERT.1.3G as template in a PCR producing the final 1.3 kb fragment that was 
cloned as described above. The mutation ABC was obtained by generating by PCR 
amplification of a fragment of 0.5 kb with primers p1328f and CBF-Cr and with 
phTERT.1.3G as template. In a second PCR a 0.2 kb fragments was generated with primers 
CBF-B2f and CBF-A2r and with phTERT.1.3G as template. These two products were used as 
primers with phTERT.1.3G as template in a PCR producing the final 1.3 kb fragment that was 
cloned as described above. All the plasmids were sequenced and mutations were also 
confirmed by restriction digests. 
5.3.3 DNA oligonucleotides.  
The following DNA oligonucleotides were purchased from Microsynth (Balgach, 
Switzerland) and used for hTERT reporter constructs: 
P1r: 5'-GGAACTAGTAGATCTCGCGGGGGTGGCCGGGG-3’;  
P1328f: 5'-GGAGGAATCCAGGGAGGGTGCGAGGCC-3'; 
CBF-A2r: 5’-AGTAGATCTCGCGGGGGTGGCCGGGGCCAGGGCTGGCCACGTGCGCA-3’; 
CBF-B2f: 5’-AGGACCGCGCTGGCCACGTGGCGG-3’; 
CBF-Cr: 5’-GAGAAAGGGTGGCCAATGGAGCCAGG-3’. 
5.3.4 Transient transfections 
Transient transfections with calcium-phosphate precipitates were performed as 
described (Jordan et al., 1996). Cells were co-transfected with 1 µg pSV2-Thy-1.1 as 
reference plasmid and equimolar amounts of GFP-reporter plasmids. The total amount of 
plasmid was kept constant (6 µg) by adding pUC19. GFP reporter expression was measured 
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as described in chapter 3, except that the GFP expression of the reporter was normalized to 
that obtained upon transfection of a plasmid containing the wild type hTERT fragment 
phTERT.1.3dG. 
5.3.5 Infections.  
Amphotrophic pBNotch1IC-R and pBNotch1IC-D retroviruses were generated by 
calcium-phosphate transfections of amphotropic Phoenix cells. 48 hours to 72 hours post 
transfection the viral supernatant was collected, filtered to remove packaging cells (0.45 µm 
filters, Millipore) and stored at –70°C in 1 ml aliquots. Target cells were infected with virus 
supplemented with 8 µg/ml polybrene (Sigma). Infected cells were selected 48 h after 
infection with the appropriate drugs (0.4 mg/ml hygromycin, 1 µg/ml puromycin; 
Calbiochem). Lentivirus pAT-1-Notch1IC-D containing Notch1IC-D under the control of the 
pGK promoter was kindly provided by Kenneth Raj (ISREC). 
5.3.6 Quantitative RT-PCR analysis.  
Total RNA was extracted and RT-PCRs were performed as described in (Ducrest et al., 
2001). The following primers were used to detect HES1 RNA: HES1-102fw: 5’-
CAGAAAGTCATCAAAGCCTATTATGG-3’; HES1-179rv: 5’-
CTTTCTTCAGAGCATCCAAAATCA-3’ (Microsynth, Switzerland). They spanned the 
boundary between exon 2 and exon 3 of hHES1 thus amplifying only cDNA derived from 
spliced RNA. RT-PCR of mouse RNA was performed as described (Ducrest et al., 2001) with 
the following modifications. Total RNA of murine livers was treated with DNaseI prior to 
RT-PCR. Murine β2-Microglobulin RNA was used as endogenous control to normalize the 
amount of RNA of each reaction. The concentration of the mβ2M primer was 600 µM for the 
forward and 900 µM for the reverse primer. mTERT and mβ2M RNA were amplified with 
the following primer pairs:  
mTERT2616fw: 5’-TTTCTGTTGGTGACGCCTCA-3’;  
mTERT2693rv: 5’-CCCATACTCAGGAACGCCAT-3; 
mβ2Mfw: 5’-TCTGGTGCTTGTCTCACTGACC-3’; 
mβ2Mrv: 5’-CAGTATGTTCGGCTTCCCATT-3’. 
5.3.7 Generation of mice with loxP-flanked Notch1 allele and activation of the Cre 
recombinase.  
Notch1lox/lox (thereafter called WT) and Notch1lox/lox Mx-Cre (thereafter called KO) mice 
were generated as described previously (Radtke et al., 1999). To induce the Cre-recombinase, 
adult mice received three intraperitoneal injections of 250 µg polyI-polyC (Sigma Chemical 
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Co.) at 2 day intervals (Radtke et al., 1999). Fifteen days (2 WT and 3 KO) and 22 days (2 
WT and 4 KO) after the last injection mice were killed. Total RNAs were prepared from their 
livers, washed in PBS and dounce homogenized. One third of homogenized livers were used 
for total RNA extraction. 
5.3.8 Immunoblots.  
Total protein from four livers of WT and KO mice was extracted with 8M urea, 0.5% 
Triton X-100 and 0.5% NP40. Seventy-five µg of protein/lane was resolved on a 6 % SDS-
polyacrylamide gel and transferred to a protein nitrocellulose membrane. The membrane was 
stained with Ponceau to control for loading and transfer. mNotch1 was detected with a goat 
polyclonal antibody (M-20, dilution 1/100, Santa Cruz). Western blots were developed using 
the enhanced chemiluminescence system (ECL, Amersham). 
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5.4 RESULTS 
5.4.1 Comparison of the 5’flanking region of human and rodent TERT genes 
Conservation of binding sites in the 5’flanking regions of homologous genes suggests 
that the same transcription factors regulate these genes. In order to look for such binding sites 
in the TERT genes, the 4 kb fragment upstream of the translation start site of the mTERT 
gene (AF 121949) was compared to the 7.4 kb fragment upstream of the translation start site 
of the hTERT gene (AF114847), using Dotter ((Sonnhammer and Durbin, 1995). When both 
sequences were compared, only two regions showed high similarity (Fig. 2). These two 
fragments are located 5580 to 5360 bp and 1220 to 1420 bp upstream of the ATG of hTERT, 
respectively. Both regions do contain neither repetitive elements nor obvious transcription 
binding sites (TRANSFAC 4.0, Quandt et al., 1995 and PatSearch, Heinemeyer et al., 1998). 
Moreover, when the expression of GFP-reporter containing and deleted of these regions were 
compared, no significant difference in GFP expression was observed in telomerase positive or 
negative cells (data not shown). Thus it is not clear whether these two regions play a role in 
the regulation of the hTERT gene.  
It is expected that in the most proximal 5’ flanking region of the human and mouse 
TERT genes, where in both genes the transcription start sites and putative binding sites for c-
Myc and SP1 are located, the sequences should be highly similar. In contrast to the 
expectation, only very weak similarity was observed. The absence of high conservation 
between the 5’flanking regions of rodent and human TERT could explain the differential 
expression between hTERT and mTERT genes. In rodents TERT expression is maintained 
during differentiation (Russo et al., 1998), whereas hTERT expression is limited to stem cells 
and activated lymphocytes (Chiu et al., 1996; Wright et al., 1996). 
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Figure 2: Comparison of the 5’UTR regions upstream of the translation start site of the hTERT and 
mTERT. The 7.4 kb of hTERT gene are plotted against the 4 kb of the mTERT gene. Good matches (matrix 
identity) are shown by a darker trait on the diagonal. Two regions show some similarity, that is 5450 bp and 
1300 bp upstream of the hTERT gene upstream of the translation start site.  
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5.4.2 The proximal upstream region of the hTERT gene contains putative CBF1 
binding sites 
CBF1 recognizes the core DNA sequence GTGGGAA and interacts weakly with ACT 
and CG sequences flanking this heptanucleotide 5’ and 3’ (Tun et al., 1994). CBF1 binding 
sites have been shown to play a role in the regulation of human Cyclin D1 (Ronchini and 
Capobianco, 2001), NF-κB (Oswald et al., 1998; Palmieri et al., 1999), IL-6 (Kannabiran et 
al., 1997) genes, of mouse HES1 genes (Tun et al., 1994), of Drosophila Enhancer of split 
gene complex (Bailey and Posakony, 1995), of the Epstein Barr virus genes such as EBNA2 
(Ling et al., 1993) or LMP1 (Ling et al., 1994) and of the adenovirus pIX gene (Dou et al., 
1994). In these genes one to three 7 bp consensus or imperfect 6 bp CBF1 binding sites in the 
sense and antisense orientation are located in the proximal part of the promoter, between 500 
to 150 bp upstream of the transcription start sites. The activity of the binding of CBF1 to the 
DNA was shown by reporter assays, EMSA and by purification of CBF1 from the binding 
site. CBF1 binding sites were also found in enhancer. In the human β-globin gene the CBF1 
binding sites overlaps a putative E box in the hypersensitive site 2 (HS2) of the locus control 
region 10 to 50 kb upstream of the β-globin gene (Lam and Bresnick, 1998).  
The hTERT gene contains putative CBF1 binding sites (Fig. 3). In the 5’flanking region 
one putative binding site overlaps with the putative E box located at position –31 bp upstream 
of the translation start site. A second site lies 826 bp upstream of the translation start site in 
the antisense orientation (Fig. 3). We also found perfect consensus sequences in the second, 
third and sixth introns of hTERT gene at positions 2057, 11660 and 14988 bp downstream of 
the translation start site, respectively (according to AF128893; (Wick et al., 1999). In the 
5’flanking region the second E box (-240 bp) overlaps with an imperfect 6 bp putative CBF1 
binding site present in an antisense orientation (Fig. 3).  
Since the first 800 bp upstream of the ATG are not conserved between mouse and 
human, it is suspected that the CBF1 binding sites are missing in the mouse. Perfect 
consensus binding sites are missing in the mouse TERT gene. But two less well-conserved 
consensi of 6 bp are found. One overlaps with the putative E box 23 bp upstream of the 
translation start site. A second imperfect CBF1 binding sites lies 115 bp upstream of the 
translation start site in the antisense orientation. These observations suggest that CBF1 may 
play a role in hTERT, but not in mTERT regulation.  
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-833 ccatttccca ccctttctcg acgggaccgc cccggtgggt gattaacaga 
tttggggtgg 
………………… 
-293 ggccgggctc ccagtggatt cgcgggcaca gacgcccagg accgcgctcc 
ccacgtggcg 
-233 gagggactgg ggacccgggc acccgtcctg ccccttcacc ttccagctcc 
gcctcctccg 
-173 cgcggacccc gccccgtccc gacccctccc gggtccccgg cccagccccc 
tccgggccct 
-113 cccagcccct ccccttcctt tccgcggccc cgccctctcc tcgcggcgcg 
agtttcaggc 
 -53 agcgctgcgt cctgctgcgc acgtgggaag ccctggcccc ggccaccccc 
gcgatg 
Figure 3: CBF1 binding sites in hTERT 5’flanking region. The putative CBF1 binding sites are shown in 
red and violet. The putative c-Myc binding sites are shown in violet and blue. Violet represents the overlapping 
part between the putative CBF1 and c-Myc binding sites. Negative numbers represent the position of the 
nucleotides relative to the translation start site. The major transcription start site lies between –55 and – 77 (MA 
unpublished data, (Horikawa et al., 1999; Takakura et al., 1999; Wick et al., 1999). 
5.4.3 Ectopic expression of Notch1IC increases hTERT RNA expression in 21NT scells 
To determine whether RNA levels of hTERT are modulated by Notch, we over-
expressed two different mouse Notch1IC constructs in tumor-derived cell lines and primary 
cells and monitored their ability to modulate hTERT and HES1 RNA levels by quantitative 
RT-PCR. Mouse Notch1IC has been shown to be able to activate target genes in human cell 
lines (Jarriault et al., 1995). In one of the Notch1IC constructs, Notch1IC-R, the OPA and 
PEST sequences are missing (Fig. 1). Since it was recently described that the OPA sequences 
may be important for Notch1IC transactivation (Kurooka et al., 1998) and for the interaction 
of Notch1IC with PCAF (Kurooka and Honjo, 2000) we also tested a construct, Notch1IC-D, 
in which only the PEST sequences are missing (Fig. 1) (Deftos et al., 1998). In 21NT cells, 
expression of the Notch1IC-R increased hTERT and HES1 RNA levels 4 - 6 fold (Fig. 4), 
whereas GAPDH or β2-microglobulin were unchanged (data not shown). A 2 – 4 fold 
increase of hTERT and HES1 RNA was also detected with the Notch1IC-D (Table 1). A 
similar increase in nuclear, intron-containing hTERT RNA was observed (Table 1) (see 
chapter 4; (Ducrest et al., 2001), suggesting that Notch1IC acts on hTERT transcription and 
not on hTERT splicing or hTERT nuclear export.  
We also followed in a time course experiment the RNA levels of hTERT and HES1 in 
21NT cells infected with lentivirus expressing Notch1IC-D (Fig. 5). Eight hours post-
infection, HES1 RNA levels increased 2 fold, while an increase in hTERT RNA was detected 
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only after 16 hours. Both transcripts reached a maximal increase of 3 fold 16h post-infection 
upon which they decreased again. The observation that the increase in HES1 RNA preceded 
the one of hTERT sensibly suggests that the constitutive active form of Notch1 might have 
activated hTERT transcription indirectly. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Relative hTERT and HES1 RNA levels in 21NT cells infected with pBabeNotch1IC 
retroviruses. Subconfluent 21NT cells were infected with pBP-NotchIC retroviruses and selected for 7 days with 
puromycin. Extracted RNA was reverse transcribed and analyzed by quantitative PCR. hTERT and HES1 RNA 
were normalized to GAPDH and expressed relative to the amount of RNA in the control cells infected with pBP. 
The average and standard deviations of hTERT (blue) and HES1 (violet) RNA measured in 2 different infections 
are represented.  
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Figure 5: Delayed timing of hTERT induction in 21NT infected with Notch1IC-D lentivirus. Extracted 
RNA was processed and normalized as described in figure 1.  
 
 
 
 
Table 1: hTERT and HES1 RNA levels in 21NT expressing Notch1IC.  
Constructs hTERT1 SD3 HES11 SD3 n4 
pBP-NOTCH1IC-R 4.6 1.1 6.0 1.3 2 
0 
2 
4 
6 
8 
hTERT HES
1 
RNA 
levels 
relative 
to 
control 
cells 
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pBP-NOTCH1IC-R 4.02  3.1  1 
pBH-NOTCH1IC-R 2.0 0.3 2.4 0.5 2 
pBP-NOTCH1IC-D 3.0 1.5 3.9 2.1 5 
hTERT/HES11:average RNA levels relative to control cells; Spliced hTERT RNA was detected with pimer pairs 
E9-10, except for 4.02: detection of intron 2-containing hTERT RNA using primer pair E2-I2 (Ducrest et al., 
2001). SD3: standard deviation; n4: number of different infections. 
5.4.4 Ectopic expression of Notch1IC did not affect endogenous hTERT RNA levels in 
telomerase negative cells 
We also tested if Notch would be sufficient to induce hTERT expression in telomerase 
negative cells. For this experiment we used human lung fibroblasts (HLF), human mammary 
epithelial cells (HMEC) and 21NT-chromosome-3 hybrids, in which the transfer of a normal 
chromosome 3 turns off expression of endogenous hTERT (see chapter 3; (Ducrest et al., 
2001). The latter cells were rescued from senescence by ectopic expression of a hTERT 
cDNA construct. Following ectopic expression of Notch1IC-R in HLF cells, a 3 to 10 fold 
induction of HES1 RNA was detected while hTERT RNA could not be detected (Table 2). 
With the same viruses only a slight induction in HES1 transcripts was detected in HMEC and 
21NT-chromosome-3 hybrid cells and no signal above the detection limit was detected for 
endogenous hTERT RNA (Table 2). Thus Notch1IC is not sufficient to induce hTERT RNA 
expression in the telomerase negative cells that were tested.  
Whereas over-expression of Notch1IC induced hTERT in 21NT (see above), a different 
effect was observed in HLF-c-Myc and in HeLa cells. Here hTERT RNA levels decreased 2 
to 3 fold, whereas HES1 RNA levels increased 5 and 2 fold, respectively (Table 2). This 
suggests that in HeLa and HLF-c-Myc, Notch1IC may induce repressors of hTERT or that 
Notch1IC may compete with activators of hTERT for hTERT promoter binding sites.  
 
Table 2: hTERT and HES1 RNA levels in cells expressing Notch1IC-R. 
Cells hTERT1 SD2 HES11 SD2 n3 
21NT-chromosome-3 hybrids BG4  1.8 0.5 4 
HMEC BG4  1.4 0.1 2 
HLF BG4  6.8 5.3 2 
HLF-c-Myc 0.3 0.0 1.4 0.1 2 
HeLa 0.5 0.3 4.6 3.1 3 
hTERT/HES11:average RNA levels relative to control cells, SD2: standard deviation, n3: number of 
different infections, BG4: RNA levels below the detection limit. 
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5.4.5 Mutations in putative CBF1 binding sites do not affect hTERT-GFP reporter 
expression  
Competition between Notch1IC and c-Myc for binding in the hTERT promoter is an 
attractive hypothesis, since two of the CBF1 and c-Myc binding sites are overlapping (Fig. 2). 
To examine the role of the putative CBF1 binding sites on hTERT expression, point 
mutations affecting only the CBF1 binding sites were introduced in GFP-reporter constructs 
containing 1.3 kb of the hTERT upstream region (Fig. 3B, chapter 4; (Ducrest et al., 2001). 
Their effects were tested in HeLa, 21NT, 21NT Notch1IC, 21NT-chromosome-3, HLF and 
HLF-c-Myc cells. The point mutations did not affect GFP expression in 21NT, 21NT-
Notch1IC, 21NT-chromosome 3 and HeLa cells, even when combined in the same reporter 
construct (data no shown). In another study, the proximal putative CBF1 binding site was 
identified as a binding site (called MT box) for a DNA binding activity in gel shift assays 
(Braunstein et al., 2001).  
5.4.6 Notch1 knockout and wild-type mice have similar mTERT RNA levels 
Mouse and human TERT are differently regulated since in contrast to hTERT, mTERT 
is expressed in the majority of somatic cells (Blasco et al., 1995), (Sugaya et al., 1997). To 
determine whether Notch1 controls mTERT expression, we monitored the mTERT RNA 
levels in wild type and conditional knockout mice. Five wild type and seven conditional 
knockout mice were sacrificed and RNA was extracted from their livers, in which high 
efficiency of Notch1 deletion was observed (Fig. 7A). In liver of adult man, Notch1 was 
shown to be expressed weakly in biliary epithelial cells and hepatocytes, and strongly in liver 
endothelial cells (Nijjar et al., 2001). Therefore, Notch1 is expressed in the majority of the 
liver cells. The livers of knockout mice appear smoother and bigger than wild-type (data not 
shown), suggesting that knocking out the Notch1 gene has a broad effect on livers. Moreover 
patients suffering of the Alagille syndrome due to a nonsense mutation in the binding partner 
of Notch1, Jagged1, develop cholestatic liver and intrahepatic ductal paucity (Louis et al., 
1999). In contrast, the expression pattern of mTERT in liver cells is not precisely known. No 
difference in mTERT RNA levels between the knockout and wild type mice was detected 
(Fig.7B). This suggests that mTERT may not be regulated by Notch1. This result may be 
explained by the absence of putative CBF1 binding sites in the 5’ flanking region of the 
mTERT gene. However a high expression of mTERT in liver cells that do not express Notch1 
could also mask the effect of knocking out the Notch1 gene on mTERT. 
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Figure 7: mTERT RNA levels are not affected by Notch1. A: Notch1 deletion was controlled in the liver 
of 2 wild-type and 2 KO mice by western blot (on the right) using antibodies specific for mNotch1. The arrows 
show the position of full length (300 kD) and intracellular Notch1 (120 kD). On the left a ponceau staining 
shows that equal amounts of proteins were loaded. B: Liver of Notch1IC KO and wild-type mice have the same 
levels of mTERT RNA. Average (±SD) of mTERT RNA levels in Notch1IC KO (KO) mice relative to wild-type 
(WT) mice are represented. Total RNA was extracted from the livers of 7 KO and 5 WT mice. 
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5.5 DISCUSSION 
 
Our results show that Notch1IC can modulate hTERT RNA levels in some cell types 
whereas no effect on mTERT RNA was observed in conditional Notch1IC knockout mice. 
Ectopic Notch1IC increased in 21NT partially spliced hTERT RNA as well as nuclear, intron-
containing immature hTERT RNA 2 - 4 folds. This suggests that Notch1IC activates hTERT 
transcription (Ducrest et al., 2001). However Notch1IC over-expression was not sufficient to 
overcome hTERT repression in telomerase negative primary mammary epithelial cells 
(HMEC), primary lung fibroblasts (HLF) or 21NT-chromosome 3 hybrids. Why Notch1IC 
overexpression caused a decrease of hTERT RNA and an increase of HES1 RNA levels 
observed in HeLa cells and in HLF-c-Myc is not clear. It is possible that HES1, which can 
bind to E-boxes and acts as a repressor, competes with c-Myc for binding the hTERT gene. It 
is also possible that HES1 decreases endogenous Notch levels in a feedback loop or that 
ectopic Notch1IC may titrate out an activator of hTERT or activates a repressor of hTERT.  
It is unclear if Notch1IC acts directly on the hTERT gene. Mutations of the putative 
CBF1 binding sites in hTERT-GFP reporters did not affect the expression of GFP in 21NT, 
21NT-Notch1IC, 21NT-chromosome 3 and HeLa cells. However, since we showed that the 
reporters did not mimic endogenous hTERT expression, this results is not conclusive (Chapter 
2 and 4; (Ducrest et al., 2001; Ducrest et al., 2002). In the time course experiment, hTERT 
induction upon Notch1IC over-expression was delayed relative to HES1, which is a direct 
target of Notch1. This result supports the notion that hTERT induction by Notch1IC may be 
indirect. To answer this question further chromatin immunoprecipitation (ChIP) experiments 
could be carried out.  
The biological significance of Notch1 for hTERT regulation remains elusive. It could 
regulate hTERT expression during differentiation in embryonic cells. During embryonic 
development, Notch is expressed in undifferentiated cells and controls cell differentiation. In 
human, telomerase activity correlates with Notch expression being limited to germ-line 
tissues, blastocysts and to 16 to 20 week old fetal tissues (Ulaner and Giudice, 1997; Wright 
et al., 1996). Notch signaling has been shown to accelerate progression through the G1 phase 
in HL60 promyelocytic leukemia (Carlesso et al., 1999) and to activate CBF1-mediated 
transcription of the cyclin D1 gene (Ronchini and Capobianco, 2001), thus promoting S-phase 
entry. Levels of hTERT RNA are sensitive to the proliferative state and decrease in arrested 
cells (Chapter 4; (Ducrest et al., 2001). Telomerase activity is detected in 85% of tumor-
derived cells (Kim et al., 1994). Inappropriate expression of Notch1 and Notch2 has been 
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observed in numerous human cancers of different origins (Aster et al., 1994; Daniel et al., 
1997; Ellisen et al., 1991; Zagouras et al., 1995). Finally truncated forms of Notch1, Notch2 
and Notch4/Int3 have been demonstrated to have transforming activity in several different 
systems (Dievart et al., 1999; Gallahan et al., 1987; Girard et al., 1996; Pear et al., 1996; 
Robbins et al., 1992; Rohn et al., 1996; Ronchini and Capobianco, 2000; Smith et al., 1995). 
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6 CONCLUDING REMARKS 
This work contributes to the understanding of the mechanisms that control hTERT 
expression. First, we have quantified hTERT RNA molecules in telomerase negative and 
positive cells. In all telomerase positive cells hTERT RNA levels were detectable but at a 
very low level (0.2 to 6 molecules/cell). In telomerase negative cells hTERT RNA could not 
be detected (<0.004 molecules/cell). We compared the levels of spliced cytoplasmic hTERT 
RNA with intron-containing nuclear hTERT RNA in telomerase positive and negative cells. 
This showed that intron-containing nuclear hTERT RNA is present only in telomerase 
positive cells. These results strongly suggest that hTERT RNA levels are controlled at the 
level of transcription. However, this does not exclude that regulation involves also changes in 
the efficiency of nuclear processing of primary transcripts. 
Second, we demonstrated that the hTERT reporters containing up to 7.5 kb of the 
5’flanking region do not faithfully mimic endogenous hTERT RNA expression. Comparing 
related telomerase positive and negative cells showed that hTERT-GFP reporters were 
expressed in certain cell lines that do not contain detectable levels of hTERT transcripts. 
These cell lines are a SV40-immortalized cell line that maintains its telomeres by the 
alternative pathway (ALT) and a breast cancer cell line (21NT), in which the transfer of an 
extra chromosome 3 extinguished hTERT RNA expression (21NT-chromosome 3). Thus 
endogenous hTERT expression may be controlled either by cis-acting elements located 
outside of the 5’flanking region analyzed, or by the chromatin structure at the endogenous 
hTERT locus. It may also be possible that telomeric silencing influences hTERT expression, 
since the gene is located near the telomere of chromosome 5p (Bryce et al., 2000). 
Third, we characterized candidate hTERT regulators. We assessed the role of c-Myc in 
21NT-chromosome 3 hybrids and of the Notch signaling pathway for regulating hTERT in 
several tumor-derived and primary cells. c-Myc had been shown to directly activate hTERT 
expression in EBV-immortalized B lymphocytes and in embryonic lung fibroblasts 
(Greenberg et al., 1999; Oh et al., 2000; Wu et al., 1999). Transfer of chromosome 3 
decreased  hTERT RNA levels 30 fold without altering the expressions of c-Myc and its 
target genes. This suggests that the putative repressor on chromosome 3 does not mediate its 
effect via c-Myc.  
Notch is involved in controlling cell differentiation and is over-expressed in some 
cancers. Therefore Notch might also regulate hTERT expression. Indeed, over-expression of 
Notch1IC increased hTERT expression in the breast tumor-derived cell line from epithelial 
origin, 21NT, reduced hTERT transcripts in a cervical carcinoma cell line, HeLa, and in c-
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Myc transformed primary fibroblasts. Ectopic Notch1IC expression had no detectable effect 
in hTERT RNA levels of telomerase negative cells tested. We also found putative CBF1 
binding sites in the hTERT gene, supporting the notion that Notch1IC directly bind hTERT 
via CBF1. However, this has not been assed directly. 
As mentioned above, there are a low number of hTERT RNA molecules in telomerase 
positive cells. We also found that the level of hTERT RNA does not vary during the cell cycle 
and that hTERT RNA has an intermediate stability with a half-life of 2h in a telomerase 
positive cell. This indicates that only one or two polymerases may transcribe hTERT gene at 
any given time. This low level of gene transcription is not too unusual, since in mammalian, 
cells the steady state levels of the majority of mRNAs are below 10 copies per cell (Jackson et 
al., 2000). The low copy number of hTERT mRNA must be sufficient for the synthesis of 
enough hTERT protein molecules to stabilize the telomere length of 46 chromosomes 
(Hemann et al., 2001). As each mRNA molecule can be translated many times, one single 
copy of hTERT mRNA might allow the synthesis of more than 200’000 protein molecules 
during one cell cycle, if one assumed a translation rate of 250 amino acids per minute and one 
initiation event per 0.4 minutes. Moreover hTERT protein is stable with a half-life of 24h 
(Holt et al., 1997). It is also possible that besides maintaining telomere length, hTERT RNA 
expression is detrimental for some cell processes. However, ectopic expression of hTERT in 
telomerase negative cell restores telomerase activity and extends their lifespan (Bodnar et al., 
1998; Vaziri and Benchimol, 1998) and no cellular defect has been reported (Morales et al., 
1999). Since telomerase repression may have tumor suppressive function, telomerase may 
only be expressed in the cell types that undergo a high number of cell divisions during our 
lifespan. Thus regulation of hTERT expression is tissue-dependent. Therefore, multiple 
regulators of hTERT expression may be required (Chapter 2; (Ducrest et al., 2002).  
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